WO1999007413A1 - Substance p inhibitors in combination with nmda-blockers for treating pain - Google Patents

Substance p inhibitors in combination with nmda-blockers for treating pain Download PDF

Info

Publication number
WO1999007413A1
WO1999007413A1 PCT/US1998/010707 US9810707W WO9907413A1 WO 1999007413 A1 WO1999007413 A1 WO 1999007413A1 US 9810707 W US9810707 W US 9810707W WO 9907413 A1 WO9907413 A1 WO 9907413A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
group
phenyl
amine
methoxy
Prior art date
Application number
PCT/US1998/010707
Other languages
French (fr)
Inventor
Frank S. Caruso
Original Assignee
Algos Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algos Pharmaceutical Corporation filed Critical Algos Pharmaceutical Corporation
Priority to AU76960/98A priority Critical patent/AU7696098A/en
Publication of WO1999007413A1 publication Critical patent/WO1999007413A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046Tachykinins, e.g. eledoisins, substance P; Related peptides

Definitions

  • This invention relates to an analgesic composition and method for alleviating pain. More particularly, this invention is concerned with alleviating pain by administration of an analgesic composition comprising a substance P receptor antagonist and, as a potentiator of the substance P receptor antagonist, a nontoxic N- methyl-D-aspartate (NMDA) receptor antagonist and/or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.
  • an analgesic composition comprising a substance P receptor antagonist and, as a potentiator of the substance P receptor antagonist, a nontoxic N- methyl-D-aspartate (NMDA) receptor antagonist and/or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.
  • NMDA N- methyl-D-aspartate
  • Substance P receptor antagonist shall be understood to be synonymous with and/or inclusive of neurokinin-1, or NK-1, receptor antagonist.
  • Substance P is a naturally occurring undecapeptide that belongs to the tachykinin family of peptides. Specifically, substance P is a pharmacologically active neuropeptide that is produced in mammals. Its characteristic amino acid sequence is illustrated in U.S. Patent No. 4,680,283.
  • the neuropeptide receptors for substance P are distributed throughout the mammalian nervous system, e.g., the brain and spinal ganglia, the circulatory system and peripheral tissues such as the duodenum and jejunum. Substance P is believed to be involved in the transmission of pain.
  • an analgesic composition which comprises (a) an analgesically effective amount of at least one substance P receptor antagonist and (b) a substance P receptor antagonist-potentiating amount of at least one substance P receptor antagonist potentiator selected from the group consisting of nontoxic N-methyl-D-aspartate receptor and nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation.
  • a method for alleviating pain comprises administering to a mammal exhibiting pain (a) an analgesically effective amount of at least one substance P receptor antagonist and (b) a substance P receptor antagonist-potentiating amount of at least one substance P receptor antagonist potentiator selected from the group consisting of nontoxic N-methyl-D- aspartate receptor antagonist and nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation.
  • N-methyl-D-aspartate receptor shall be understood to include all of the binding site subcategories associated with the NMDA receptor, e.g., the gly cine-binding .site, the phenylcyclidine (PCP)-binding site, etc., as well as the NMDA channel.
  • the invention herein contemplates the use of nontoxic substances that block an NMDA receptor binding site, e.g., dextromethorphan, or that block the NMDA channel, e.g., a source of magnesium such as magnesium sulfate.
  • nontoxic as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United States Food and Drug Administration (“FDA”) for administration to humans or, in keeping with established regulatory criteria and practice, is susceptible to approval by the FDA for administration to humans.
  • FDA United States Food and Drug Administration
  • nontoxic is also used herein to distinguish the NMDA receptor antagonists, or blockers, that are useful in the practice of the present invention from NMDA receptor antagonists such as MK 801 (the compound 5-methyl-10,ll-dihydro-SH-dibenze[a,d] cyclohepten-5,10-imine), CPP (the compound 3-[2-carboxypiperazin-4-yl] propyl- 1-phosphonic acid) and PCP (the compound l-(l-phenylcyclohexyl)piperidine) whose toxicities effectively preclude their therapeutic use.
  • MK 801 the compound 5-methyl-10,ll-dihydro-SH-dibenze[a,d] cyclohepten-5,10-imine
  • CPP the compound 3-[2-carboxypiperazin-4-yl] propyl- 1-phosphonic acid
  • PCP the compound l-(l-phenylcyclohexyl)piperidine
  • potentiate and “potentiating” are used herein in their art- recognized sense, i.e., as referring to a significant increase in the level of analgesic activity for the combination of substance P receptor antagonist and nontoxic NMDA receptor antagonist and/or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation compared with that which could have been expected based on the activities of the substance P receptor antagonist administered alone and nontoxic NMDA receptor antagonist and/or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation administered alone.
  • analgesically effective amount as applied to the substance P receptor antagonist employed in the analgesic composition and method of this invention shall be understood to mean an amount of substance P receptor antagonist which when administered by itself or in combination with the nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation provides effective analgesia.
  • substance P receptor antagonists heretofore used to treat pain and/or a disorder exhibiting a pain component e.g., muscular pain, musculoskeletal pain, chronic pain, neuropathic pain, migraine, etc.
  • a pain component e.g., muscular pain, musculoskeletal pain, chronic pain, neuropathic pain, migraine, etc.
  • Specific substance P receptor antagonists that can be used herein are disclosed in aforementioned U.S. Patent Nos.
  • useful substance P receptor antagonists include the substance P analogs of U.S. Patent No. 3,862,114, e.g., compounds having the L- amino acid sequence G-L-M-NH 2 , O-G-L-M-NH 2 , F-G-L-M-NH 2 and the like; the undecapeptides of U.S. Patent No.
  • 3,912,711 e.g., L-arginyl-L-prolyl-L-lysyl-L- prolyl-L-glut ⁇ minyl-L-glutammyl-L-phenylalanyl-L-glycyl-L-leucyl-L-memionine amide and the like; the hexapeptide amides of U.S. Patent No.
  • 5,102,667 e.g., 2-[l-imino- 2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4-perhydroisoindolone in its (3aR,7aR) or (3aR,7aRS) forms, 7,7-diphenyl-2-[2-(2-dimethylaminophenyl)acetyl]-4-perhydro- isoindolone in its (3aR,7aR) or (3aRS,7aRS) forms, 7,7-diphenyl-2-[(R)-2-(2- methoxyphenyl)propionyl]-4-perhydroisoindolone in its (3aR,7aR) or (3aRS,7aRS) forms and the like; the quinuclidines of U.S.
  • Patent No. 5,232,929 e.g., cis-3-(2-methoxybenzylamino)-2-phenylpiperidine, cis-l-allyl-3-(2- methoxybenzylamino)-2-phenylpiperidine, cis-l-ethyl-3-(2-methoxybenzylamino)-2- phenylpiperidine and the like; the dialkylenepiperidinos of U.S. Patent Nos.
  • N-[4-(l-benzyl-4- ⁇ i ⁇ eridinyl)-2-(3,4-dichlorophenyl)-butyl]-4- fluoronaphtalene carboxamide hydrochloride N-[4-[l-(fluorobenzyl)-4-piperidiny_]-2- (3,4-dichlorophenyl)-butyl]-2,4-dichlorobenzamide hydrochloride, N-methyl-N-[4-(l- benzyl-4-piperidinyl)-2-(3,4-dichlorophenyl)-butyl]3-isopropoxy-phenylacetamide hydrochloride and the like; the 1-acylpiperidines of U.S.
  • Patent Nos. 5,310,743 and 5,541,195 e.g., (2R,4S) and (2R,4R)-2-benzyl-l-(3,5-dimethyl-benzoyl)-N-(2- phenethyl)-4-piperidinamine hydrochloride, (2R*,4S*)-2-benzyl-l-(2-naphthoyl)-N-(4- quinolylmethyl)-4-piper idinamine , (2R* ,4S *)-2-benzy 1- 1 -(3 -tri-fluoromethylbenzoy 1)- N-(4-quinolylmethyl)-4-piperidinamine and the like; the cyclic dimeric dipeptide derivatives of U.S.
  • Patent No. 5,411,971 e.g., N-[2-(3,4-dichlorophenyl)-4-(4-(2-pyridylthio)-l-piperidinyl)butyl]-2,4- dichlorobenzamide, N-[4-(4-N ' -acetylanilino- 1 -piperidinyl)-2-(3 ,4- dichlorophenyl)buty 1] -N-methylbenzamide , N-[4-( 1 -methy 1-2-imidazoly l)-4-thio- 1 - piperidinyl)-2-naphthylbutyl]-2,4-dimethoxybenzamide and the like; the peptides of U.S.
  • Patent No. 5,420,297 e.g., Boc-Phe (p-CH 3 )-OH, Boc-Phe(p-F)-OH and the like; the quinuclidines of U.S. Patent No. 5,422,354, e.g., 8-(diphenylmethyl)-N-((2- methoxyphenyl)methyl))-9-azatricyclo[4.3.1.0 4,9 ]decan-7-amine, 8-(diphenylmethyl)-N- (phenylmethyl)-9-azatricyclo[4.3.1.0 4 ' 9 ]decan-7-amine, 8-(diphenylmethyl)-N-((2- chlorophenyl)methyl))-9-azatricyclo[4.3.1.0 4,9 ]decan-7-amine and the like; the 3-a ⁇ ino- 2-arylquinuclidines of U.S.
  • Patent No. 5,536,737 e.g., (S)-2-[[(S)-2-(acetoxyacetyl)-l-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-l- pyrrolidinecarboxamide , (S)-2- [[(S)-2-(hy dr oxy acetyl)- 1 -pyrrolidinyl] carbony 1] -N- (phenylmethyl)-l-pyrrolidinecarboxamide, (S)-2-[[(S)-2-[(benzoyloxyacetyl)-l- pyrrolidinyl]carbonyl]-N-(phenylmethyl)-l-pyrrolidinecarboxamide and the like; the pseudopeptides of U.S.
  • Patent No. 5,561,113 e.g., ⁇ l-[4-(lH-tetrazol-5-yl)- butyl)indol-3-yl ⁇ carbonyl-Hyp-Nal-NMeBzl, ⁇ l-[4-(lH-tetrazol-5-yl)buty_]indol-3- yl ⁇ carbonyl-Hyp-Tna-NMeBzl, ⁇ l-[4-(lH-tetrazol-5-yl)butyl]indol-3-yl ⁇ carbonyl-Hyp- Thn-NMeBzl and the like; the piperidines of U.S. Patent No.
  • Patent No. 5,624,950 e.g., 7,7-dimethyl-4-(2- methoxyphenyl)-2-[2-(S)-(2-methoxyphenyl)propionyl]-4,5-perhydroisoindolediol, 4-(2- methoxyphenyl)-2-[2-(S)-(2-methoxyphenyl)proponyl]-5-methyl-4-perhydro-isoindolol, 2-[2-(S)-(2-hydroxyphenyl)propionyl]-4-(2-methoxyphenyl)-6-methyl-4- perhydroisoindolol and the like; the substituted pyrrolidin-3-yl-alkyl-piperidines of U.S..
  • Patent No. 5,635,510 e.g., (+)-or(-)-l-(2-[3-(3,4-dichloro-phenyl)-l-[2-(2- methoxy-phenyl)-acetyl]-pyrrolidin-3-yl]-ethyl)-4-phenyl-piperidine-4-carboxylic.acid amide , ( + )-or (-)- 1 - [2- [3-(3 , 4-dichlorophenyl)- 1 -(2 , 6-dimethoxybenzoy l)-py rrolidin-3 - yl] -ethyl] -4-phenyl-piperidine-4-carboxy lie acid amide, (+)-or(-)-l-[2-[3-(3,4-dichloro- phenyl)- 1 (3,4 , 5-trimethoxybenzoyl)-pyrrolidin-3 -yl] -ethy
  • WO 91/09844 e.g., cis-3-(2-chlorobenzylamino)-2-phenyl-piperidine, cis-3-(2-trifluoromethylbenzylamino)-2-phenylpiperidine, cis-3-(2- methoxybenzylamino)-2-(2-fluorophenyl)-piperidine and the like; the peptides of World Patent Application No. WO 91/12266, e.g., the compounds of Examples 1-34 and the like; the fused ring analogs of nitrogen containing heterocycles of World Patent
  • WO 92/15585 e.g., 2-(diphenylmethyl)-N-((2-methoxyphenyl)-methyl)-l- azabicyclo[3.2.2]nonan-3-amine, 2-(diphenylmethyl)-N-((2-chlorophenyl)-methyl)-l- azabicyclo [3.2.2] nonan-3 -amine , 2-(dipheny lmethy l)-N-((2 , 4-dimethoxy- phenyl)methyl)-l-azabicyclo[3.2.2]nonan-3-amine and the like; the N,N-diacyl- piperazines of World Patent Application No.
  • WO 92/2066 e.g., l,4-bis(N,N- diphenylcarbamoyl)piperazine-2-carboxylic acid, 1 ,4-bis(N,N-diphenylcarbamoyl)-2- methy 1-piperazine , 1 -(N , N-di-n-penty lcarbamoy l)-4-(N , N-dipheny lcarbamoy 1)- piperazine-2-carboxylic acid and the like; the substituted 3-aminoquinuclidines of World Patent Application No.
  • WO 92/20676 e.g., (3R,4S,5S,6S)-N,N-diethyl-5-(2,5- dimethoxybenzy lamino)-6-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octane-3 -carboxamide , (3R,4S,5S,6S)-5-(5-isopropyl-2-memoxybenzyl. ⁇ mino)-6-diphenylmethyl-l-azabicyclo- [2.2.2]octane-3-carboxylic acid, (3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzyl- amino)-6-diphenylmethyl-l-azabicyclo[2.2.2]octane-3-carboxylic acid and the like; the quinuclidines of World Patent Application No.
  • WO 92/21677 e.g., (2S,3S)-N-(5- isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-l-azabicyclo[2.2.2]octan-3- amine , (2S , 3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenyl-methyl- 1 -azabicyclo- [2.2.2]octan-3-amine, (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenyl- methyl-l-azabicyclo[2.2.2]octan-3-amine and the like; the peptides of World Patent Application No.
  • WO 92/22569 e.g., the compounds of Examples 1-22 and the like; the azanorbornane compounds of World Patent Application No. WO 93/00330, e.g., (lSR,2SR,3SR,4RS)-l-aza-2-di ⁇ henylmethyl-3-[(2-methoxyphenyl)methylamino]- bicyclo[2.2.1]heptace, (lSR,2SR,3SR,4RS)-l-aza-2-diphenylmethyl-3-[(2-methoxy-5- (l,l-dimethylethyl)phenyl)methylamino]bicyclo[2.2.1]heptane, (1SR,2SR,3SR,4RS)-1- aza-2-diphenylmethyl-3-[(2-methoxy-5-trifluoromethoxyphenyl)methylamino]bi- cyclo[2.2.1]heptane and the like; the fluoroalkoxybenzylamino derivative
  • WO 93/00033 e.g., (2S,3S)-2-phenyl-3-[2-(2,2,2-trifluoroethoxy)-benzyl]aminopiperidine, 2-(di- pheny lmethy l)-N-((2-difluoromethoxy)pheny l)methy 1- 1 -azabicy clo [2.2.2] octan-3 -amine , (2S,3S)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-2-diphenylmethyl-l- azabicyclo[2.2.2]octane-3-amine and the like; the fused tricyclics of World Patent Application No.
  • WO 93/01159 e.g., l-(5H-dibe_ ⁇ zo[a,d]cyclohepten-5-y_)-2-(3,5- dimethylbenzyloxy)ethylamine, N-acetamido-l-(5H-dibenzo[a,d]cyclohepten-5-yl)-2- (3,5-dimethylbenzyloxy)ethylamine, 1-(10, 1 l-dihydro-5H-dibenzo[a,d]cyclohepten-5- yl)-2-(3,5-dimethylbenzyloxy)ethylamine and the like; the aromatic compounds of World Patent Application No.
  • WO 93/01160 e.g., 2-ammonium-l-((3,5-dimethyl- phenyl)methyloxy)-3,3-diphenylpropane, 2-dimethylammonium-l-((3,5-dimethyl- phenyl)methyloxy)-3 ,3-diphenylpropane, 2-t-butoxycarbonylamino-3 ,3-diphenyl- propanoyl-(2-methoxyphenyl)methylamide and the like; the aromatic compounds of World Patent Application No.
  • WO 93/01165 e.g., L-l-((3,5-bis(trifluoromethyl)- phenyl)methyloxy)-2-(t-butoxycarbonylamino)-2-phenylethane, 1 -((3 ,5-dimethyl- phenyl)methyloxy)-2(S)-2-(((carbomethoxy)methyl)amino)-2-phenylethane, (2S)-2- (((carboxamido)methyl)a ⁇ _monium)-l-((3,5-dimethylphenyl)methyloxy)-2-phenylethane and the like; the aromatic compounds of World Patent Application No.
  • WO 93/01169 e.g., 3,5-dimethylbenzyl 2-(l,l-dimethylethoxycarbonyla ⁇ o)-3-(3-indolyl)propionate, 3,5-dimethylbenzyl 2-acetamido-3-(3-indolyl)propionate; 3,5-dimethylbenzyl 2- cyclohexanecarboxamido-3-(3-indolyl)propionate and the like; the 3-aminopiperidines of World Patent Application No.
  • WO 93/01170 e.g., (2S,3S)-3-(4,5-difluoro-2- methoxybenzyl)amino-2-phenylpiperidine, (2S,3S)-3-(2-cyclopentyl-oxy-5- methoxybenzyl)amino-2-phenylpiperidine, (2S,3S)-3-(5-sec-butyl-2-methoxy- benzyl)amino-2-phenylpiperidine and the like; the fused tricyclic nitrogen containing heterocycles of World Patent Application No.
  • WO 93/06099 e.g., ( ⁇ tis-9- diphenylmethyl-N-((2-methoxyphenyl)methyl)- 10-azatricyclo[4.4.1. O ⁇ Jundecan- ⁇ - amine , (+)-cis-9-diphenylmethyl-N-(2-methoxy-5-chlorophenyl)- 10-azatricyclo- [4.4.1.C ⁇ undecan- ⁇ -amine, ( + )-cis-9-diphenylmethyl-N-(2-trifiuoromethoxypheny D- 10-azatricyclo[4.4.1.0 5,7 ]undecan-8-amine and the like; the acyclic ethylenediamines of World Patent Application No.
  • WO 93/10073 e.g., l-amino-l-phenyl-2-[(2-methoxy)- phenylmethylamino]propane, (lR ⁇ 2S -l-cyclohexyla ⁇ _ino-l-phenyl-2-[(2-met_ ⁇ oxy)- pheny lmethy lamino] propane , 1 -N-cy clohexy 1- 1 -pheny 1-2-N ' - [(2-methoxy-5 -tr ifluoro- methoxyphenyl)methyl]-l,2-ethanediamine and the like; the piperidines of World Patent Application No.
  • WO 93/14084 e.g., l-[2-(5-fluoro-lH-indol-3-yl)ethyl]-4-[((2- methyl)phenylsulf ⁇ nyl)methyl]-4-piperidinol, l-[2-(5-fluoro-lH-indol-3-yl)ethyl]-4-[((4- methyl)pheny lsulfiny l)methy 1] -4-piper idinol , 1 - [2-(5-fluor o- 1 H-indol-3 -y l)ethy 1] -4- [(phenylsulf ⁇ nyl)methyl]-4-piperidinol and the like; the quinuclidines of World Patent Application No.
  • WO 93/19064 e.g., (3R,4S,5S,6S)-N-carbamoylmethyl-5-(5-iso- propy 1-2-methoxybenzy l-amino)-6-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octane-3 - carboxamide, (3R,4S,5S,6S)-N-carboxymethyl-5-(5-isopropyl-2-methoxybenzylamino)- 6-diphenylmethyl- 1 -azabicyclo[2.2.2] octane-3 -carboxamide , (3R,4S ,5S , 6S)-3-(2- carbamoylpyrrolidin-l-yl)carbonyl-5-(5-isopropyl-2-methoxybenzyl_ ⁇ mino)-6- diphenylmethyl-l-azabicyclo[2.2.2]octane and the like
  • WO 93/21155 e.g., diphenyl-7,7 (methoxy-2 phenyl)- 4[(methoxy-2 phenyl)-2 propionyl]-2 perhydroisoindolol-4, diphenyl-7,7 (methoxy-2 phenyl)-4 [(methoxy-2 phenyl)-2 propionyl]-2 perhydroisoindolediol-4,5, diphenyl-7,7 (methoxy -2 pheny l)-4 [(hydroxy-2 phenyl)-2 acetyl] -2 perhydroisoindolol-4 and the like; the substituted benzylamino nitrogen containing non-aromatic heterocycles of World Patent Application No.
  • WO 94/08997 e.g., (2S,3S)-N-(5-isopropenyl-2- methoxypheny l)methy 1-2-dipheny lmethy 1- 1 -azabicy clo [2,2.2] octan-3 -amine , (2S , 3 S)-N- (2-methoxy-5-viny lpheny l)methyl-2-dipheny lmethy 1- 1 -azabicy clo [2,2.2] octan-3 -amine , (2S,3S)-N-(2-methoxy-4,5-dimethylphenyl)methyl-2-diphenylmethyl-l- azabicyclo[2.2.2]octan-3-amine and the like; the N-benzoyl-4-oxy/thio-2-substituted piperidines of World Patent Application No.
  • EP 327009 e.g., the compounds of Examples 1-5 and the like
  • the peptides of European Patent Application No. EP 333174 e.g., Boc-Gin-D-Trp(CHO)-Phe-Nmebzl, Boc-Thr-D-Trp(CHO)-Phe- NMeBzl, Boc-Glu(NMe 2 )-D-Trp(CHO)-Phe-NMeBzl and the like
  • the peptides of European Patent Application No. EP 336230 e.g., the compounds of Example 1-22 and the like
  • EP 394989 e.g., the compounds of Examples 1-63 and the like; the aromatic amines of European Patent Application No. 428434, e.g., N[(benzyl-4-piperidinyl-l)-4(dichloro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide, N[(benzyl-4 piperidinyl-l)-4(difluoro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide, N[(benzyl-4 piperidinyl-l)-4(dichloro-3,4 phenyl)-2 butyl] fluoro-4 naphthalene- 1 carboxamide and the like; the isoindolones of European Patent Application No.
  • EP 429366 e.g., diphenyl-7,7[dimethylamino-2 phenyl)-2 acetyl]-2 perhydroisoindolone-4, diphenyl-7,7[methoxy-2 phenyl)-2 propionyl-(R)]-2 perhydroisoindolone-4, [(5)-carboxy benzylimino-l (methoxy-2 phenyl)-2 ethyl]-2 diphenyl-7,7 perhydroisoindolone-4 and the like; the peptides of European Patent Application No. EP 443132, e.g., the compounds of Examples 1-9 and the like; the azabicyclics of European Patent Application No.
  • EP 499313 e.g., trans-3-[3,5- bis(trifluoromethy l)benzyloxy] -2-(dipheny lmethy 1)- 1 -azabicy clo [2.2.2] octane , trans-3- [3 ,5-dimethoxybenzy loxy] -2-(dipheny lmethy 1)- 1 -azabicy clo [2.2.2] octane , trans-2- (diphenylmethyl)-3-(3-phenoxybenzyloxy)-l-azabicyclo[2.2.2]octane and the like; the polycyclic amines of European Patent Application No.
  • EP 512901 e.g., chlorhydrate of 5-[2-(4-benzyl-l-piperidinyl)ethyl]-5-(3,4-dichlorophenyl)-l-benzyl-piperidinone, chlorohydrate of 3-[2-(4-benzyl-l-piperidinyl)ethyl]-3-(3 ,4-dichlorophenyl)-l- phenylacetylpiperidine, chlorohydrate of 3-[2-(4-benzyl-l-piperidinyl)ethyl]-3-(3,4- dichlorophenyl)-l-(3-isopropoxyphenyl)acetylazepine and the like; the dialkylenepiperidinos of European Patent Application No.
  • EP 512902 e.g., chlorohydrate of N-[ ⁇ 4-[l-benzyl-piperidin-4-yl]-2-(3,4-dichlorophenyl) ⁇ -butyl]-4- fluoronaphtalenecarboxamide, chlorohydrate of N-[ ⁇ 2-(3,4-dichlorophenyl)-4-[l-(4- fluorobenzyl)-piperidin-4-yl] ⁇ -butyl]-2,4-dichlorobenzamide, chlorohydrate of N- methyl-N- ⁇ 4-[l-benzyl-piperidine-4-yl]-2-(3,4-dichlorophenyl) ⁇ -butyl]-3- isopropoxyphenylacetamide and the like; the perhydroisoindoles of European Patent Application No.
  • EP 514273 e.g., ⁇ [(pyrrolidinyl- 1)-3 propoxy-2]phenyl ⁇ acetyl-2 diphenyl-4,4 fluoro-7 perhydroisoindole, diphenyl-4,4 fluoro-7 [(methoxy-2 phenyl)-2 propionyl-(S)]-2 perhydroisoindole, [(dimethylamino-3 propoxy)-2 phenyl] acety 1-2 diphenyl-4,4 fluoro-7 perhydroisoindole and the like; the thiopyranipyrroles of European Patent Application No.
  • EP 514275 e.g., ⁇ [(dimethylamino-3 propoxy-2) phenyl]acetyl)-6 diphenyl-4,4-oxyde-l perhydrothiopyrano[2,3-c]pyrrole, ⁇ [(pyrrolidinyl-l)-3 propoxy-2] phenyl ⁇ acetyl ⁇ -6 diphenyl-4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole, [ ⁇ methoxy-2 phenyl)-2 propionyl-(S)]-6 diphenyl- 4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole and the like; the azabicyclics of European Patent Application No.
  • EP 520555 e.g., 3-[(3,5-dimethylphenyl)methoxy]-2- (l,2-diphenylethyl)_-l-azabicyclo[2.2.2]octane, 3-[(3,5- bistrifluoromethy lpheny l)methoxy] -2-( 1 , 2-diphenylethy 1)- 1 -azabicy clo [2.2.2] octane , 3 - [(3,5-bistrifluoromethylphenyl)methyloxy]-2-[l-(l-(4-methoxyphenyl)-2-phenyl)ethyl]- l-azabicyclo[2.2.2]octane and the like; the aromatic compounds of European Patent Application No.
  • EP 522808 e.g., 2-ammonium-3,3-diphenylpropanoyl-(2- methoxyphenyl)methylamide, (3 ,5-dimethyl-phenyl)methyl-2-ammonium-3 ,3- diphenylpropanoate, 2-methylammonium-l-((3,5-dimethylphenyl)methyloxy)-3,3- diphenylpropane and the like; the azacyclics of European Patent Application No. EP 528495 , e. g.
  • EP 532456 e.g., (2R*,4S*)-2- benzyl- l-(2-naphthoyl)-N-(4-chinoly lmethy l)-4-piperidinamin, (2R*,4S*)-2-benzyl-l-(3- trifluoromethylbenzoyl)-N-(4-chinolylmethyl)-4-piperidinamin, (2R*,4S*)-2-benzyl-l- (3,5-bis-(trifluoromethyl)-benzoyl)-N-(4-chinolylmethyl)-4-piperidinamin and the like; and the peptides of GB 2216529, e.g., cyclo(Gln-Tr ⁇ -Phe-(R)Gly[ANC-2]Leu-Met, cyclo(Gln-Npa-Phe-(R)Gly[ANC-2]Leu-Met, cyclo(Gl
  • nontoxic substances that block the NMDA receptor and as such are useful for enhancing the analgesic activity of a substance P receptor antagonist in accordance with this invention are dextromethorphan ((+)-3-hydroxy-N- methylmorphinan) and its metabolite dextrorphan ((+)-3-hydroxy-N- methy Imorphinan), their mixtures and their pharmaceutically acceptable salts.
  • Other useful nontoxic substances that block the NMDA receptor include amantadine (1- aminoadamantine), memantine (3,5-dimethylaminoadamantone), pyrroloquinoline quinone and cis-4-(phosphonomethyl)-2-piperid_necarboxylic acid.
  • dextromethorphan in the form of its hydrobromide salt is preferred for use herein due to its ready availability and its established use in over-the- counter medications where it functions as a cough suppressant. While dextrorphan and its pharmaceutically acceptable salts will also provide excellent results, it is not known to be in commercial manufacture at this time.
  • At least one nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation can also be used.
  • Activation of the NMDA receptor a subtype of excitatory amino acid receptors, induces a number of changes in the functional activity of nerve cells and, in particular, their capacity for excitability or inhibition in the presence of an addictive substance via an increase in intracellular Ca+ -I- concentration.
  • NMDA receptor activation includes the following sequences, or cascades, of events occurring within nerve cells: a) translocation and activation of protein kinases such as protein kinase C - phosphorylation of substrate proteins such as cytosolic enzymes, channel proteins, receptor proteins, etc.
  • protein kinases such as protein kinase C - phosphorylation of substrate proteins such as cytosolic enzymes, channel proteins, receptor proteins, etc.
  • ⁇ changes in functional activity b) initiation of early gene (c-fos, c-jun, zif-26$, etc.) expression by either increased intracellular Ca+ + or Ca+ + -activated protein kinases - expression of functional genes responsible for production of cellular enzymes (such as protein kinases), receptor proteins (such as the NMDA receptor), ion channel proteins (such as K+ , Na+ , Ca+ + channels), neuropeptides (such as dynorphin), etc. - changes in functional activity; c) Ca+ +/calmodulin (or other Ca+ + binding proteins) induced activation of enzymes and other cellular components - activation of
  • Ca+ +/calmodulin-protein kinase systems such as Ca+ +/calmodulin kinase II - autophosphorylation of enzymes (e.g., Ca-f- +/calmodulin kinase II) or other functional proteins - changes in functional activity; d) Ca+ +/calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase - production of nitric oxide ⁇ i) production of cyclic guanosine monophosphate via activation of guanosine cyclase resulting in activation of protein kinases and early gene expression; ii) direct protein modification such as enzymes, receptor and/or channel proteins; iii) lipid membrane modification and/or nucleic acid modification via scavenge of free radicals; iv) induction of neurotoxicity at higher nitric oxide levels; v) retrograde actions in adjacent neurons or glial cells such as
  • a substance that blocks the NMDA receptor will effectively prevent all of the foregoing major intracellular sequences of events from taking place.
  • the substance P receptor antagonist and a nontoxic substance that blocks at least one of the foregoing major intra-cellular sequences of events brought about by activation of the NMDA receptor.
  • a substance that interferes with translocation and activation of protein kinase C or with calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase is also useful for the practice of this invention.
  • NMDA receptor activation and are therefore useful in the practice of the invention include inhibitors of protein kinase C, e.g., gangliosides such as ganglioside GM ! (monosialoganglios.de) and ganglioside GT b (trisialoganglioside); amphipathic long chain bases such as sphingosine, N,N,N-trimethylsphingosine, sphinganine and psychosine; quinolyloxazole-2-ones such as 4-methyl-5-(3-quinolinyl)-2-(3H)-oxazolone and phenyl-5-(2-quinolinyl)-2-3(3H)-oxazolone; 1 ,4-bis-(amino-hydroxyalkylamino)- anthraquinones such as l,4-bis-(3-propylamino-2-hydroxypropylamino)-9,10 anthracenedione and 1
  • Additional nontoxic substances that block a major intracellular consequence of NMDA receptor activation and as such are useful in the practice of the invention include inhibitors of calmodulin such as the phenothiazines, in particular, chlorpromazine, chlorpromazine sulfoxide, prochlorperazine dimaleate, perphenazine, trifluoperazine, fluphenazine, fluphenazine enanthate, fluphenazine decanoate, thioridazine, mesoridazine besylate, piperacetazine, acetophenazine dimaleate, carphenazine dimaleate, butaperazine dimaleate and phenothiazine sulfoxide; naphthalenesulfonamides such as N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide, N-(6-aminohexyl)-5-chloro-2-n
  • the nontoxic NMDA receptor antagonists are preferred and of these, dextromethorphan is preferred for the reasons previously stated.
  • the substance P receptor antagonist must be present in an analgesically effective amount, e.g., at a level corresponding to the generally recommended adult human dosages for a particular substance P receptor antagonist, and the nontoxic NMDA receptor antagonist or substance that blocks a major intracellular consequence of NMDA activation must be present at a level that potentiates the therapeutic effectiveness of the substance P receptor antagonist.
  • NMDA receptor antagonist and nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation separately, as a matter of convenience, it is preferred that they be coadministered as a single analgesic composition.
  • All modes of administrations are contemplated, e.g. ⁇ orally, rectally, parenterally, topically, or by intravenous, intramuscular, intrastemal or subcutaneous injection or in a form suitable by inhalation.
  • the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy.
  • analgesic composition containing the substance P receptor antagonist and nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation will ordinarily be formulated with one or more pharmaceutically acceptable ingredients in accordance with known and established practice.
  • the analgesic composition can be formulated as a liquid, powder, elixir, injectable solution, etc.
  • Formulations for oral use can be provided as tablets or hard capsules wherein the pharmacologically active ingredients are mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients are mixed with water or miscible solvents such as propylene glycol; PEG's and ethanol, or an oleaginous medium, e.g., peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin
  • water or miscible solvents such as propylene glycol; PEG's and ethanol
  • an oleaginous medium e.g., peanut oil, liquid paraffin or olive oil.
  • the analgesic composition herein can take the form of a buccal or sublingual tablet, drops or lozenges formulated in a known or conventional manner.
  • the analgesic composition of the invention can be formulated as a cream, gel, ointment or lotion or as a transdermal patch.
  • Such composition can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening, gelling, emulsifying, stabilizing, dispersing, suspending and/or coloring agents.
  • the analgesic composition of the invention can also be formulated as a sustained release preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the analgesic composition can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the analgesic composition of the invention can be formulated for parenteral administration by injection, conveniently intravenous, intramuscular or subcutaneous injection, for example, by bolus injection or continuous intravenous infusion.
  • Formulations for injection can be presented in unit dosage, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the analgesic composition can take a variety of forms such as a suspension, solution or emulsion in an oily or aqueous vehicle and can contain one or more formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the analgesic composition can be provided in powder form for dissolution in a suitable vehicle, e.g. sterile pyrogen-free water, before administration.
  • the analgesic composition of the invention can also be formulated as a rectal composition, e.g., a suppository or retention enema containing conventional suppository bases such as cocoa butter or other glyceride(s).
  • a rectal composition e.g., a suppository or retention enema containing conventional suppository bases such as cocoa butter or other glyceride(s).
  • the analgesic composition is conveniently delivered in the form of an aerosol spray by means of a pressurized container or a nebulizer employing a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoro- ethane, heptafluoropropane, carbon dioxide, and the like.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoro- ethane, heptafluoropropane, carbon dioxide, and the like.
  • the dosage unit can be regulated by means of a metering valve.
  • Aqueous suspensions can include pharmaceutically acceptable excipients such as suspending agents, e.g., sodium carboxymethyl cellulose, methy lcellulose, hy droxypropy lmethy lcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, e.g, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g.,
  • the aqueous suspensions can also contain one or more preservatives, e.g., ethyl-or-n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate.
  • preservatives e.g., ethyl-or-n-propyl-p-hydroxy benzoate
  • coloring agents e.g., ethyl-or-n-propyl-p-hydroxy benzoate
  • flavoring agents e.g., ethyl-or-n-propyl-p-hydroxy benzoate
  • sweetening agents such as sucrose, saccharin or sodium or calcium cyclamate.
  • the analgesic composition herein can contain at least one other pharmacologically active substance, e.g., a non-narcotic analgesic such as tramadol, acetaminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, zomepirac, and die like, or a narcotic analgesic such as codeine, oxycodone,
  • Example Substance P Receptor Antagonist (mg . Blocker (mg . Component (mg) 1 pyroglutamyl-phenylalanyl-N-methyl- dextromethorphan pheny lalanyl-[(R)-3-amino-2-oxo- 1 - hydrobromide (30) pyrrolidine-(S)-4-methyl-2-pentanoyl] methionine amide (25) [U.S. Patent No.
  • Example Substance P Receptor Antagonist (mg. Blw er (mg) Component (mg) 4 2-[l-imino-2-(2-methoxy ⁇ henyl)ethyl]-7,7- dextromethorphan diphenyl-4-perhydroisoindolone in its hydrobromide (30) (3aR,3aR) or (3aR,7aRS) forms (25) [U.S. Patent No.
  • Example Substance P receptor antagonist (mg . Blocker (mg. Component (mg.
  • Example Substance P receptor antagonist (mg. Blocker (mg. Component (m .
  • Example Substance P receptor antagonist (mg . Blocker (m . Component .mg) 34 trans-2-phenyl-N-(2-methoxyphenyl) dextromethorphan methyl)-l-azabicyclo[2.2.2]octan-3- hydrobromide (30) amine (25) [U.S. Patent No. 5,451,586] 35 ⁇ l-[4-(lH-tetrazol-5-yl)butyl]indol-3-yl ⁇ dextromethorphan carbonyl-Hyp-Thn-Nmebzl (25) hydrobromide (30) [U.S. Patent No. 5,561,113]
  • the nontoxic NMDA receptor antagonist dextromethorphan hydrobromide significantly potentiates the analgesic activity of the substance P receptor antagonist.

Abstract

The analgesic effectiveness of a substance P receptor antagonist is significantly potentiated by administering a substance P receptor antagonist with a nontoxic NMDA receptor antagonist and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation.

Description

SUBSTANCE P INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN
BACKGROUND OF THE INVENTION
This invention relates to an analgesic composition and method for alleviating pain. More particularly, this invention is concerned with alleviating pain by administration of an analgesic composition comprising a substance P receptor antagonist and, as a potentiator of the substance P receptor antagonist, a nontoxic N- methyl-D-aspartate (NMDA) receptor antagonist and/or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.
The expression "substance P receptor antagonist" shall be understood to be synonymous with and/or inclusive of neurokinin-1, or NK-1, receptor antagonist. Substance P is a naturally occurring undecapeptide that belongs to the tachykinin family of peptides. Specifically, substance P is a pharmacologically active neuropeptide that is produced in mammals. Its characteristic amino acid sequence is illustrated in U.S. Patent No. 4,680,283. The neuropeptide receptors for substance P are distributed throughout the mammalian nervous system, e.g., the brain and spinal ganglia, the circulatory system and peripheral tissues such as the duodenum and jejunum. Substance P is believed to be involved in the transmission of pain. A large number of substance P receptor antagonists have been described in the patent literature as suitable for alleviating pain and/or ameliorating any of a variety of disorders that are commonly accompanied by pain. See, e.g., U.S. Patent Nos. 3,862,114, 3,912,711, 4,472,305, 4,481,139, 4,680,283, 4,839,465, 5,102,667, 5,162,339, 5,164,372, 5,166,136, 5,232,929, 5,300,648, 5,310,743, 5,338,845, 5,340,822, 5,378,803, 5,410,019, 5,411,971, 5,420,297, 5,422,354, 5,446,052, 5,451,586, 5,525,712, 5,527,811, 5,536,737, 5,541,195, 5,561,113, 5,576,317, 5,604,247, 5,624,950 and 5,635,510; World Patent Application Nos. WO 90/05525, WO 91/09844, WO.91/12266, WO 92/06079, WO 92/12151, WO 92/15585, WO 92/20661, WO 92/20676, WO 92/21677, WO 92/22569, WO 93/00330, WO 93/00331, WO 93/01159, WO 93/01160, WO 93/01165, WO 93/01169, WO 93/01170, WO 93/06099, WO 93/10073, WO 93/14084, WO 93/19064, WO 93/21155, WO 94/04496, WO 94/08997 and WO 95/11895; European Patent Application Nos. 284942, 327009, 333174, 336230, 360390, 394989, 428434, 429366, 443132, 446706, 484719, 499313, 512901, 512902, 514273, 514275, 520555, 522808, 528495 and 532456; and GB 2216529.
SUMMARY OF THE INVENTION
In accordance with the present invention, an analgesic composition is provided which comprises (a) an analgesically effective amount of at least one substance P receptor antagonist and (b) a substance P receptor antagonist-potentiating amount of at least one substance P receptor antagonist potentiator selected from the group consisting of nontoxic N-methyl-D-aspartate receptor and nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation. Further in accordance with this invention, a method for alleviating pain is provided with comprises administering to a mammal exhibiting pain (a) an analgesically effective amount of at least one substance P receptor antagonist and (b) a substance P receptor antagonist-potentiating amount of at least one substance P receptor antagonist potentiator selected from the group consisting of nontoxic N-methyl-D- aspartate receptor antagonist and nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation.
The expression "N-methyl-D-aspartate receptor" shall be understood to include all of the binding site subcategories associated with the NMDA receptor, e.g., the gly cine-binding .site, the phenylcyclidine (PCP)-binding site, etc., as well as the NMDA channel. Thus, the invention herein contemplates the use of nontoxic substances that block an NMDA receptor binding site, e.g., dextromethorphan, or that block the NMDA channel, e.g., a source of magnesium such as magnesium sulfate. The term "nontoxic" as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United States Food and Drug Administration ("FDA") for administration to humans or, in keeping with established regulatory criteria and practice, is susceptible to approval by the FDA for administration to humans. The term "nontoxic" is also used herein to distinguish the NMDA receptor antagonists, or blockers, that are useful in the practice of the present invention from NMDA receptor antagonists such as MK 801 (the compound 5-methyl-10,ll-dihydro-SH-dibenze[a,d] cyclohepten-5,10-imine), CPP (the compound 3-[2-carboxypiperazin-4-yl] propyl- 1-phosphonic acid) and PCP (the compound l-(l-phenylcyclohexyl)piperidine) whose toxicities effectively preclude their therapeutic use.
The terms "potentiate" and "potentiating" are used herein in their art- recognized sense, i.e., as referring to a significant increase in the level of analgesic activity for the combination of substance P receptor antagonist and nontoxic NMDA receptor antagonist and/or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation compared with that which could have been expected based on the activities of the substance P receptor antagonist administered alone and nontoxic NMDA receptor antagonist and/or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation administered alone.
The expression "analgesically effective amount" as applied to the substance P receptor antagonist employed in the analgesic composition and method of this invention shall be understood to mean an amount of substance P receptor antagonist which when administered by itself or in combination with the nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation provides effective analgesia.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Any of the substance P receptor antagonists heretofore used to treat pain and/or a disorder exhibiting a pain component, e.g., muscular pain, musculoskeletal pain, chronic pain, neuropathic pain, migraine, etc., can be used herein. Specific substance P receptor antagonists that can be used herein are disclosed in aforementioned U.S. Patent Nos. 3,862,114, 3,912,711, 4,472,305, 4,481,139, 4,680,283, 4,839,465, 5,102,667, 5,162,339, 5,164,372, 5,166,136, 5,232,929, 5,300,648, 5,310,743, 5,338,845, 5,340,822, 5,378,803, 5,410,019, 5,411,971, 5,420,297, 5,422,354, 5,446,052, 5,451,586, 5,525,712, 5,527,811, 5,536,737, 5,541,195, 5,561,113, 5,576,317, 5,604,247, 5,624,950 and 5,635,510; World Patent Application Nos. WO 90/05525, WO 91/09844, WO 91/12266, WO 92/06079, WO 92/12151, WO 92/15585, WO 92/20661, WO 92/20676, WO 92/21677, WO 92/22569, WO 93/00330, WO 93/00331, WO 93/01159, WO 93/01160, WO 93/01165, WO 93/01169, WO 93/01170, WO 93/06099, WO 93/10073, WO 93/14084, WO 93/19064, WO 93/21155, WO 94/04496, WO 94/08997 and WO 95/11895; European Patent Application Nos. 284942, 327009, 333174, 336230, 360390, 394989, 428434, 429366, 443132, 446706, 484719, 499313, 512901, 512902, 514273, 514275, 520555, 522808, 528495 and 532456; and GB 2216529, the contents of which are incorporated by reference herein. More particularly, useful substance P receptor antagonists include the substance P analogs of U.S. Patent No. 3,862,114, e.g., compounds having the L- amino acid sequence G-L-M-NH2, O-G-L-M-NH2, F-G-L-M-NH2 and the like; the undecapeptides of U.S. Patent No. 3,912,711, e.g., L-arginyl-L-prolyl-L-lysyl-L- prolyl-L-glutøminyl-L-glutammyl-L-phenylalanyl-L-glycyl-L-leucyl-L-memionine amide and the like; the hexapeptide amides of U.S. Patent No. 4,472,305, e.g., HPro- Phe-Phe-DAla-Leu-MetNH2, HPro-Phe-MePhe-Gly-Leu-MetNH2, HPro-Phe-Phe-Gly- DLeu-MetNH2 and the like; the undecapeptides of U.S. Patent No. 4,481,139, e.g., [D-Phe5, D-Trp7, D-Trp9, Leun]-SP, [Glp5, D-Trp7, D-Trp9, Thr"]-SPs.u, [D-Ang1, D- Tip7, D-Trp9, Leuπ]-SP and the like; the substance P analogs of U.S. Patent No. 4,680,283, e.g., pyroglutamyl-ohenylalanyl-phenylalanyl-[(R)-3-amino-2-oxo-l- pyrrolidine-(S)-4-methyl-2-pentanoyl]methionine amide, pyroglutamyl-phenylalanyl-N- memyl-phenylalanyl-[(R)-3-__mino-2-oxo-l-pyrrolidine-(S)-4-methyl-2- pentanoyl] methionine amide and the like; the di-(D-tryptophyl and/or tetra- hydropyridoindolylcarbonyl)-containing peptide amides of U.S. Patent No. 4,839,465, e.g., H-trρ-Phe-trp-Leu-Met-NH2, H-Pro-trρ-Phe-trp-Leu-Phe-NH2, H-tpi-Phe-trp-Leu: Met-NH2 and the like; the isoindolones of U.S. Patent No. 5,102,667, e.g., 2-[l-imino- 2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4-perhydroisoindolone in its (3aR,7aR) or (3aR,7aRS) forms, 7,7-diphenyl-2-[2-(2-dimethylaminophenyl)acetyl]-4-perhydro- isoindolone in its (3aR,7aR) or (3aRS,7aRS) forms, 7,7-diphenyl-2-[(R)-2-(2- methoxyphenyl)propionyl]-4-perhydroisoindolone in its (3aR,7aR) or (3aRS,7aRS) forms and the like; the quinuclidines of U.S. Patent No. 5,162,339 and World Patent Application No. WO 90/05525, e.g., cis-3-[(2-chlorophenyl)methylamino]-2-benz- hydrylquinuclidine, cis-3-[(2-trifluoromethylphenyl)methylamino]-2-benzhydryl- quinuclidine, cis-3-[(2-methoxyphenyl)methylamino]-2-benzhydrylquinuclidine and the like; the peptides of U.S. Patent No. 5,164,372, e.g., the compounds of Examples 1-63 and the like; the spirolactams of U.S. Patent No. 5,166,136 and European Patent Application No. EP 360390, e.g., 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyl]-6-oxo- (5S)-l,7-diazaspiro[4.4]nonane-l-carboxylic acid, phenylmethyl ester, 7-[(lS)-(l- methoxycarbony l)-3-methy lbuty 1] -6-oxo-(5S)- 1 , 7-diazaspiro [4.4] nonane- 1 -carboxylic acid phenylmethyl ester, 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyl]-6-oxo-(5S)-l,7- diazaspiro[4.4]nonane-l-carboxylic acid, (l,l-dimethyl)ethyl ester and the like; the 3- aminopiperidines and related nitrogen containing heterocycles of U.S. Patent No. 5,232,929, e.g., cis-3-(2-methoxybenzylamino)-2-phenylpiperidine, cis-l-allyl-3-(2- methoxybenzylamino)-2-phenylpiperidine, cis-l-ethyl-3-(2-methoxybenzylamino)-2- phenylpiperidine and the like; the dialkylenepiperidinos of U.S. Patent Nos. 5,300,648 and 5,446,052, e.g., N-[4-(l-benzyl-4-ρiρeridinyl)-2-(3,4-dichlorophenyl)-butyl]-4- fluoronaphtalene carboxamide hydrochloride, N-[4-[l-(fluorobenzyl)-4-piperidiny_]-2- (3,4-dichlorophenyl)-butyl]-2,4-dichlorobenzamide hydrochloride, N-methyl-N-[4-(l- benzyl-4-piperidinyl)-2-(3,4-dichlorophenyl)-butyl]3-isopropoxy-phenylacetamide hydrochloride and the like; the 1-acylpiperidines of U.S. Patent Nos. 5,310,743 and 5,541,195, e.g., (2R,4S) and (2R,4R)-2-benzyl-l-(3,5-dimethyl-benzoyl)-N-(2- phenethyl)-4-piperidinamine hydrochloride, (2R*,4S*)-2-benzyl-l-(2-naphthoyl)-N-(4- quinolylmethyl)-4-piper idinamine , (2R* ,4S *)-2-benzy 1- 1 -(3 -tri-fluoromethylbenzoy 1)- N-(4-quinolylmethyl)-4-piperidinamine and the like; the cyclic dimeric dipeptide derivatives of U.S. Patent No. 5,338,845, e.g., the compounds of Table 1 and the like; the polycyclic amines of U.S. Patent No. 5,340,822, e.g., 4-[2-(4-benzylpiperidin-l- yl)ethyl]-4-(3-methylphenyl)-l-(3-chlorophenyl)acetylpiperidine hydrochloride, 3-[2-(4- benzylpiperidin-l-yl)ethyl]-3-(3,4-dichlorophenyl)-l-phenylacetylpiperidine hydrochloride, 5-[2-(4-Benzylpiperidin-l-yl)ethyl]-5-(3,4-dichlorophenyl)-l- benzylpiperidinone hydrochloride and the like; the azole-fused peptides of U.S. Patent No. 5,378,803, e.g., the compounds of Examples 1-28 and the like; the peptides of U.S. Patent No. 5,410,019, e.g., H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly- Leuψ[CH2-NH]Leu-NH2, H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trpψ[CH2- NH]Leu-Nle-NH2, H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trpψ[CH2-NH]Phe-D-Trp-Leu- Nle-NH2 and the like; the N-alkylenepiperidinos of U.S. Patent No. 5,411,971, e.g., N-[2-(3,4-dichlorophenyl)-4-(4-(2-pyridylthio)-l-piperidinyl)butyl]-2,4- dichlorobenzamide, N-[4-(4-N ' -acetylanilino- 1 -piperidinyl)-2-(3 ,4- dichlorophenyl)buty 1] -N-methylbenzamide , N-[4-( 1 -methy 1-2-imidazoly l)-4-thio- 1 - piperidinyl)-2-naphthylbutyl]-2,4-dimethoxybenzamide and the like; the peptides of U.S. Patent No. 5,420,297, e.g., Boc-Phe (p-CH3)-OH, Boc-Phe(p-F)-OH and the like; the quinuclidines of U.S. Patent No. 5,422,354, e.g., 8-(diphenylmethyl)-N-((2- methoxyphenyl)methyl))-9-azatricyclo[4.3.1.04,9]decan-7-amine, 8-(diphenylmethyl)-N- (phenylmethyl)-9-azatricyclo[4.3.1.04'9]decan-7-amine, 8-(diphenylmethyl)-N-((2- chlorophenyl)methyl))-9-azatricyclo[4.3.1.04,9]decan-7-amine and the like; the 3-aπιino- 2-arylquinuclidines of U.S. Patent No. 5,451,586, e.g., trans-2-phenyl-N-(2- methoxypheny l)methy 1)- 1 -azabicy clo [2.2.2] octan-3 -amine , cis-2-pheny l-N-(pheny 1- methy 1)- 1 -azabicy clo [2.2.2] octan-3-amine , 2-( 1 -naphthyl)-N-((2-methoxy- phenyl)methyl)-l-azabicyclo[2.2.2]octan-3-amine and the like; the isoquinolinyls of U.S. Patent No. 5,527,811, e.g., N-[(6-chloro-l,2-dihydro-2-methyl-l-oxo-4- phenylisoquinolin-3-yl)methyl]-N'-(3-isopropoxyphenyl)urea, N-[(l,2-dihydro-2,6,7- trimethy 1- 1 -oxo-4-pheny lisoquinolin-3 -y l)methyl] -N ' -(3 -methy Ipheny l)urea , N- [( 1 ,2- dihydro-2-methyl-l-oxo-4-phenylisoquinolin-3yl)methyl]-N'-(3-methylphenyl)urea and the like; the prolyl endopeptidase inhibitor compounds of U.S. Patent No. 5,536,737, e.g., (S)-2-[[(S)-2-(acetoxyacetyl)-l-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-l- pyrrolidinecarboxamide , (S)-2- [[(S)-2-(hy dr oxy acetyl)- 1 -pyrrolidinyl] carbony 1] -N- (phenylmethyl)-l-pyrrolidinecarboxamide, (S)-2-[[(S)-2-[(benzoyloxyacetyl)-l- pyrrolidinyl]carbonyl]-N-(phenylmethyl)-l-pyrrolidinecarboxamide and the like; the pseudopeptides of U.S. Patent No. 5,561,113, e.g., {l-[4-(lH-tetrazol-5-yl)- butyl)indol-3-yl}carbonyl-Hyp-Nal-NMeBzl, {l-[4-(lH-tetrazol-5-yl)buty_]indol-3- yl}carbonyl-Hyp-Tna-NMeBzl, {l-[4-(lH-tetrazol-5-yl)butyl]indol-3-yl}carbonyl-Hyp- Thn-NMeBzl and the like; the piperidines of U.S. Patent No. 5,576,317, e.g., (2S.3S)- 3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine (2S,3S)- 3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine, (2S,3S)-3-(2- ethoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine and the like; the chromone compounds of U.S. Patent No. 5,604,247, e.g., (2R,4S)-N-[l-(3,5-bis- trifluoromethylbenzoyl)-2-(4-chlorobenzyl)piperidin-4-yl]-4-oxo-4H-l-benzopyrane-2- carboxamide, (2R,4S)-N-[l-(3,5-bistrifluormethylbenzoyl)-2-benzylpiperidin-4-yl]-4- oxo-4H-l-benzopyrane-2-carboxamide, (2R,4S)-N-[l-(3,5-bistrifluoromethylbenzoyl)- 2-(4-chlorobenzy l)piperidin-4-y 1] -6-fluoro-4-oxo-4H- 1 -benzopyrane-2-carboxamide and the like; the perhydroisoindoles of U.S. Patent No. 5,624,950, e.g., 7,7-dimethyl-4-(2- methoxyphenyl)-2-[2-(S)-(2-methoxyphenyl)propionyl]-4,5-perhydroisoindolediol, 4-(2- methoxyphenyl)-2-[2-(S)-(2-methoxyphenyl)proponyl]-5-methyl-4-perhydro-isoindolol, 2-[2-(S)-(2-hydroxyphenyl)propionyl]-4-(2-methoxyphenyl)-6-methyl-4- perhydroisoindolol and the like; the substituted pyrrolidin-3-yl-alkyl-piperidines of U.S.. Patent No. 5,635,510, e.g., (+)-or(-)-l-(2-[3-(3,4-dichloro-phenyl)-l-[2-(2- methoxy-phenyl)-acetyl]-pyrrolidin-3-yl]-ethyl)-4-phenyl-piperidine-4-carboxylic.acid amide , ( + )-or (-)- 1 - [2- [3-(3 , 4-dichlorophenyl)- 1 -(2 , 6-dimethoxybenzoy l)-py rrolidin-3 - yl] -ethyl] -4-phenyl-piperidine-4-carboxy lie acid amide, (+)-or(-)-l-[2-[3-(3,4-dichloro- phenyl)- 1 (3,4 , 5-trimethoxybenzoyl)-pyrrolidin-3 -yl] -ethyl] -4-pheny l- iperidine-4- carboxy lie acid amide and the like; the 3-amino-piperidines of World Patent
Application No. WO 91/09844, e.g., cis-3-(2-chlorobenzylamino)-2-phenyl-piperidine, cis-3-(2-trifluoromethylbenzylamino)-2-phenylpiperidine, cis-3-(2- methoxybenzylamino)-2-(2-fluorophenyl)-piperidine and the like; the peptides of World Patent Application No. WO 91/12266, e.g., the compounds of Examples 1-34 and the like; the fused ring analogs of nitrogen containing heterocycles of World Patent
Application No. WO 92/06079, e.g., [lα,3 ,4α,5α]-4-(2-methoxybenzyl)-amino-3- phenyl-2-azabicyclo[3.3.0]octane, 4-(2-methoxybenzyl)amino-3-phenyl-2- azabicy clo [4.4.0] decane , 4-(2-methoxybenzy l)amino-4-benzhydry 1-3-azabicy clo- [4.1.0]heptane and the like; the N-alkyl quinuclidinium salts of World Patent Application No. WO 92/12151, e.g., (2S,3S)-cis-l-methyl-2-(diphenylmethyl)-N-((2- methoxyphenyl)methy 1)- 1 -azabicy clo [2.2.2] octan-3 -amine iodide , (2S , 3 S)-cis- 1 -(4- carbethoxybutyl)-2-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-l-azabicyclo- [2.2.2]octan-3-amine iodide, (2S,3S)-cis-l-(4-carboethoxyphenylmethyl)-2- (diphenylmemyl)-N-((2-methoxyphenyl)methyl)-l-azabicyclo[2.2.2]ocl__m-3-amine iodide and the like; the l-azabicyclo[3.2.2]nonan-3 amines of World Patent Application No. WO 92/15585, e.g., 2-(diphenylmethyl)-N-((2-methoxyphenyl)-methyl)-l- azabicyclo[3.2.2]nonan-3-amine, 2-(diphenylmethyl)-N-((2-chlorophenyl)-methyl)-l- azabicyclo [3.2.2] nonan-3 -amine , 2-(dipheny lmethy l)-N-((2 , 4-dimethoxy- phenyl)methyl)-l-azabicyclo[3.2.2]nonan-3-amine and the like; the N,N-diacyl- piperazines of World Patent Application No. WO 92/20661, e.g., l,4-bis(N,N- diphenylcarbamoyl)piperazine-2-carboxylic acid, 1 ,4-bis(N,N-diphenylcarbamoyl)-2- methy 1-piperazine , 1 -(N , N-di-n-penty lcarbamoy l)-4-(N , N-dipheny lcarbamoy 1)- piperazine-2-carboxylic acid and the like; the substituted 3-aminoquinuclidines of World Patent Application No. WO 92/20676, e.g., (3R,4S,5S,6S)-N,N-diethyl-5-(2,5- dimethoxybenzy lamino)-6-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octane-3 -carboxamide , (3R,4S,5S,6S)-5-(5-isopropyl-2-memoxybenzyl.ιmino)-6-diphenylmethyl-l-azabicyclo- [2.2.2]octane-3-carboxylic acid, (3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzyl- amino)-6-diphenylmethyl-l-azabicyclo[2.2.2]octane-3-carboxylic acid and the like; the quinuclidines of World Patent Application No. WO 92/21677, e.g., (2S,3S)-N-(5- isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-l-azabicyclo[2.2.2]octan-3- amine , (2S , 3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenyl-methyl- 1 -azabicyclo- [2.2.2]octan-3-amine, (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenyl- methyl-l-azabicyclo[2.2.2]octan-3-amine and the like; the peptides of World Patent Application No. WO 92/22569, e.g., the compounds of Examples 1-22 and the like; the azanorbornane compounds of World Patent Application No. WO 93/00330, e.g., (lSR,2SR,3SR,4RS)-l-aza-2-diρhenylmethyl-3-[(2-methoxyphenyl)methylamino]- bicyclo[2.2.1]heptace, (lSR,2SR,3SR,4RS)-l-aza-2-diphenylmethyl-3-[(2-methoxy-5- (l,l-dimethylethyl)phenyl)methylamino]bicyclo[2.2.1]heptane, (1SR,2SR,3SR,4RS)-1- aza-2-diphenylmethyl-3-[(2-methoxy-5-trifluoromethoxyphenyl)methylamino]bi- cyclo[2.2.1]heptane and the like; the fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles of World Patent Application No. WO 93/000331, e.g., (2S,3S)-2-phenyl-3-[2-(2,2,2-trifluoroethoxy)-benzyl]aminopiperidine, 2-(di- pheny lmethy l)-N-((2-difluoromethoxy)pheny l)methy 1- 1 -azabicy clo [2.2.2] octan-3 -amine , (2S,3S)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-2-diphenylmethyl-l- azabicyclo[2.2.2]octane-3-amine and the like; the fused tricyclics of World Patent Application No. WO 93/01159, e.g., l-(5H-dibe_ιzo[a,d]cyclohepten-5-y_)-2-(3,5- dimethylbenzyloxy)ethylamine, N-acetamido-l-(5H-dibenzo[a,d]cyclohepten-5-yl)-2- (3,5-dimethylbenzyloxy)ethylamine, 1-(10, 1 l-dihydro-5H-dibenzo[a,d]cyclohepten-5- yl)-2-(3,5-dimethylbenzyloxy)ethylamine and the like; the aromatic compounds of World Patent Application No. WO 93/01160, e.g., 2-ammonium-l-((3,5-dimethyl- phenyl)methyloxy)-3,3-diphenylpropane, 2-dimethylammonium-l-((3,5-dimethyl- phenyl)methyloxy)-3 ,3-diphenylpropane, 2-t-butoxycarbonylamino-3 ,3-diphenyl- propanoyl-(2-methoxyphenyl)methylamide and the like; the aromatic compounds of World Patent Application No. WO 93/01165, e.g., L-l-((3,5-bis(trifluoromethyl)- phenyl)methyloxy)-2-(t-butoxycarbonylamino)-2-phenylethane, 1 -((3 ,5-dimethyl- phenyl)methyloxy)-2(S)-2-(((carbomethoxy)methyl)amino)-2-phenylethane, (2S)-2- (((carboxamido)methyl)aπ_monium)-l-((3,5-dimethylphenyl)methyloxy)-2-phenylethane and the like; the aromatic compounds of World Patent Application No. WO 93/01169, e.g., 3,5-dimethylbenzyl 2-(l,l-dimethylethoxycarbonylaπώιo)-3-(3-indolyl)propionate, 3,5-dimethylbenzyl 2-acetamido-3-(3-indolyl)propionate; 3,5-dimethylbenzyl 2- cyclohexanecarboxamido-3-(3-indolyl)propionate and the like; the 3-aminopiperidines of World Patent Application No. WO 93/01170, e.g., (2S,3S)-3-(4,5-difluoro-2- methoxybenzyl)amino-2-phenylpiperidine, (2S,3S)-3-(2-cyclopentyl-oxy-5- methoxybenzyl)amino-2-phenylpiperidine, (2S,3S)-3-(5-sec-butyl-2-methoxy- benzyl)amino-2-phenylpiperidine and the like; the fused tricyclic nitrogen containing heterocycles of World Patent Application No. WO 93/06099, e.g., (± tis-9- diphenylmethyl-N-((2-methoxyphenyl)methyl)- 10-azatricyclo[4.4.1. O^Jundecan-δ- amine , (+)-cis-9-diphenylmethyl-N-(2-methoxy-5-chlorophenyl)- 10-azatricyclo- [4.4.1.C^undecan-δ-amine, ( + )-cis-9-diphenylmethyl-N-(2-trifiuoromethoxypheny D- 10-azatricyclo[4.4.1.05,7]undecan-8-amine and the like; the acyclic ethylenediamines of World Patent Application No. WO 93/10073, e.g., l-amino-l-phenyl-2-[(2-methoxy)- phenylmethylamino]propane, (lR\2S -l-cyclohexylaπ_ino-l-phenyl-2-[(2-met_ιoxy)- pheny lmethy lamino] propane , 1 -N-cy clohexy 1- 1 -pheny 1-2-N ' - [(2-methoxy-5 -tr ifluoro- methoxyphenyl)methyl]-l,2-ethanediamine and the like; the piperidines of World Patent Application No. WO 93/14084, e.g., l-[2-(5-fluoro-lH-indol-3-yl)ethyl]-4-[((2- methyl)phenylsulfιnyl)methyl]-4-piperidinol, l-[2-(5-fluoro-lH-indol-3-yl)ethyl]-4-[((4- methyl)pheny lsulfiny l)methy 1] -4-piper idinol , 1 - [2-(5-fluor o- 1 H-indol-3 -y l)ethy 1] -4- [(phenylsulfιnyl)methyl]-4-piperidinol and the like; the quinuclidines of World Patent Application No. WO 93/19064, e.g., (3R,4S,5S,6S)-N-carbamoylmethyl-5-(5-iso- propy 1-2-methoxybenzy l-amino)-6-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octane-3 - carboxamide, (3R,4S,5S,6S)-N-carboxymethyl-5-(5-isopropyl-2-methoxybenzylamino)- 6-diphenylmethyl- 1 -azabicyclo[2.2.2] octane-3 -carboxamide , (3R,4S ,5S , 6S)-3-(2- carbamoylpyrrolidin-l-yl)carbonyl-5-(5-isopropyl-2-methoxybenzyl_ιmino)-6- diphenylmethyl-l-azabicyclo[2.2.2]octane and the like; the perhydroisoindoles of World Patent Application No. WO 93/21155, e.g., diphenyl-7,7 (methoxy-2 phenyl)- 4[(methoxy-2 phenyl)-2 propionyl]-2 perhydroisoindolol-4, diphenyl-7,7 (methoxy-2 phenyl)-4 [(methoxy-2 phenyl)-2 propionyl]-2 perhydroisoindolediol-4,5, diphenyl-7,7 (methoxy -2 pheny l)-4 [(hydroxy-2 phenyl)-2 acetyl] -2 perhydroisoindolol-4 and the like; the substituted benzylamino nitrogen containing non-aromatic heterocycles of World Patent Application No. WO 94/04496, e.g., (2S,3S)-N-(2-methoxy-5-methyl- sulfony lpheny l)-methy 1-2-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octan-3 -amine , (2S , 3 S)-N- (2-methoxy-5-methylthiopheny l)methyl-2-dipheny lmethyl- 1 -azabicyclo[2.2.2] octan-3- amine, (2S,3S)-N-(2-methoxy-5-dimethylaminophenyl)methyl-2-diphenylmethyl-l- azabicyclo[2.2.2]octan-3-amine and the like; the substituted benzylaminoquinuclidines of World Patent Application No. WO 94/08997, e.g., (2S,3S)-N-(5-isopropenyl-2- methoxypheny l)methy 1-2-dipheny lmethy 1- 1 -azabicy clo [2,2.2] octan-3 -amine , (2S , 3 S)-N- (2-methoxy-5-viny lpheny l)methyl-2-dipheny lmethy 1- 1 -azabicy clo [2,2.2] octan-3 -amine , (2S,3S)-N-(2-methoxy-4,5-dimethylphenyl)methyl-2-diphenylmethyl-l- azabicyclo[2.2.2]octan-3-amine and the like; the N-benzoyl-4-oxy/thio-2-substituted piperidines of World Patent Application No. 95/11895, e.g., (2R*,4S*)-2-benzyl-l- (3,5-bistrifluoromethylbenzoyl)-4-(4-quinolylmethoxy)-piperidine, (2R*,4S*)-quinoline- 3-carboxylic acid [2-benzyl-l-(3 ,5-bistrifluoromethylbenzoyl)-piperidin-4-yl]ester, (2R*,4S*)-2-benzyl-l-(3,5-bistrifluoromethylbenzoyl)-4-(3-quinolylmethoxy)-piperidine and the like; the compounds of European Patent Application No. EP 327009, e.g., the compounds of Examples 1-5 and the like; the peptides of European Patent Application No. EP 333174, e.g., Boc-Gin-D-Trp(CHO)-Phe-Nmebzl, Boc-Thr-D-Trp(CHO)-Phe- NMeBzl, Boc-Glu(NMe2)-D-Trp(CHO)-Phe-NMeBzl and the like; the peptides of European Patent Application No. EP 336230, e.g., the compounds of Example 1-22 and the like; the peptides of European Patent Application No. EP 394989, e.g., the compounds of Examples 1-63 and the like; the aromatic amines of European Patent Application No. 428434, e.g., N[(benzyl-4-piperidinyl-l)-4(dichloro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide, N[(benzyl-4 piperidinyl-l)-4(difluoro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide, N[(benzyl-4 piperidinyl-l)-4(dichloro-3,4 phenyl)-2 butyl] fluoro-4 naphthalene- 1 carboxamide and the like; the isoindolones of European Patent Application No. EP 429366, e.g., diphenyl-7,7[dimethylamino-2 phenyl)-2 acetyl]-2 perhydroisoindolone-4, diphenyl-7,7[methoxy-2 phenyl)-2 propionyl-(R)]-2 perhydroisoindolone-4, [(5)-carboxy benzylimino-l (methoxy-2 phenyl)-2 ethyl]-2 diphenyl-7,7 perhydroisoindolone-4 and the like; the peptides of European Patent Application No. EP 443132, e.g., the compounds of Examples 1-9 and the like; the azabicyclics of European Patent Application No. EP 499313, e.g., trans-3-[3,5- bis(trifluoromethy l)benzyloxy] -2-(dipheny lmethy 1)- 1 -azabicy clo [2.2.2] octane , trans-3- [3 ,5-dimethoxybenzy loxy] -2-(dipheny lmethy 1)- 1 -azabicy clo [2.2.2] octane , trans-2- (diphenylmethyl)-3-(3-phenoxybenzyloxy)-l-azabicyclo[2.2.2]octane and the like; the polycyclic amines of European Patent Application No. EP 512901, e.g., chlorhydrate of 5-[2-(4-benzyl-l-piperidinyl)ethyl]-5-(3,4-dichlorophenyl)-l-benzyl-piperidinone, chlorohydrate of 3-[2-(4-benzyl-l-piperidinyl)ethyl]-3-(3 ,4-dichlorophenyl)-l- phenylacetylpiperidine, chlorohydrate of 3-[2-(4-benzyl-l-piperidinyl)ethyl]-3-(3,4- dichlorophenyl)-l-(3-isopropoxyphenyl)acetylazepine and the like; the dialkylenepiperidinos of European Patent Application No. EP 512902, e.g., chlorohydrate of N-[{4-[l-benzyl-piperidin-4-yl]-2-(3,4-dichlorophenyl)}-butyl]-4- fluoronaphtalenecarboxamide, chlorohydrate of N-[{2-(3,4-dichlorophenyl)-4-[l-(4- fluorobenzyl)-piperidin-4-yl]}-butyl]-2,4-dichlorobenzamide, chlorohydrate of N- methyl-N-{{4-[l-benzyl-piperidine-4-yl]-2-(3,4-dichlorophenyl)}-butyl]-3- isopropoxyphenylacetamide and the like; the perhydroisoindoles of European Patent Application No. EP 514273, e.g., {{ [(pyrrolidinyl- 1)-3 propoxy-2]phenyl}acetyl-2 diphenyl-4,4 fluoro-7 perhydroisoindole, diphenyl-4,4 fluoro-7 [(methoxy-2 phenyl)-2 propionyl-(S)]-2 perhydroisoindole, [(dimethylamino-3 propoxy)-2 phenyl] acety 1-2 diphenyl-4,4 fluoro-7 perhydroisoindole and the like; the thiopyranipyrroles of European Patent Application No. EP 514275, e.g., {[(dimethylamino-3 propoxy-2) phenyl]acetyl)-6 diphenyl-4,4-oxyde-l perhydrothiopyrano[2,3-c]pyrrole, {[(pyrrolidinyl-l)-3 propoxy-2] phenyl} acetyl}-6 diphenyl-4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole, [{methoxy-2 phenyl)-2 propionyl-(S)]-6 diphenyl- 4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole and the like; the azabicyclics of European Patent Application No. EP 520555, e.g., 3-[(3,5-dimethylphenyl)methoxy]-2- (l,2-diphenylethyl)_-l-azabicyclo[2.2.2]octane, 3-[(3,5- bistrifluoromethy lpheny l)methoxy] -2-( 1 , 2-diphenylethy 1)- 1 -azabicy clo [2.2.2] octane , 3 - [(3,5-bistrifluoromethylphenyl)methyloxy]-2-[l-(l-(4-methoxyphenyl)-2-phenyl)ethyl]- l-azabicyclo[2.2.2]octane and the like; the aromatic compounds of European Patent Application No. EP 522808, e.g., 2-ammonium-3,3-diphenylpropanoyl-(2- methoxyphenyl)methylamide, (3 ,5-dimethyl-phenyl)methyl-2-ammonium-3 ,3- diphenylpropanoate, 2-methylammonium-l-((3,5-dimethylphenyl)methyloxy)-3,3- diphenylpropane and the like; the azacyclics of European Patent Application No. EP 528495 , e. g. , cis-2-(diphenylmethyl-3-(3 ,5-dimethylbenzyloxy)- 1 -methy lpyrrolidine, cis-3-((3 ,5-dimethylphenyl)methyloxy)-2-phenylpiperidine, cis-3-((3 ,5- dimethylphenyl)methyloxy-l-methyl-2-phenylpiperidine and the like; the 1- acylpiperidins of European Patent Application No. EP 532456, e.g., (2R*,4S*)-2- benzyl- l-(2-naphthoyl)-N-(4-chinoly lmethy l)-4-piperidinamin, (2R*,4S*)-2-benzyl-l-(3- trifluoromethylbenzoyl)-N-(4-chinolylmethyl)-4-piperidinamin, (2R*,4S*)-2-benzyl-l- (3,5-bis-(trifluoromethyl)-benzoyl)-N-(4-chinolylmethyl)-4-piperidinamin and the like; and the peptides of GB 2216529, e.g., cyclo(Gln-Trρ-Phe-(R)Gly[ANC-2]Leu-Met, cyclo(Gln-Npa-Phe-(R)Gly[ANC-2]Leu-Met, cyclo(Gln-Trp-Phe-Gly-Leu-Met and the like.
Among the nontoxic substances that block the NMDA receptor and as such are useful for enhancing the analgesic activity of a substance P receptor antagonist in accordance with this invention are dextromethorphan ((+)-3-hydroxy-N- methylmorphinan) and its metabolite dextrorphan ((+)-3-hydroxy-N- methy Imorphinan), their mixtures and their pharmaceutically acceptable salts. Other useful nontoxic substances that block the NMDA receptor include amantadine (1- aminoadamantine), memantine (3,5-dimethylaminoadamantone), pyrroloquinoline quinone and cis-4-(phosphonomethyl)-2-piperid_necarboxylic acid. Of the nontoxic NMDA receptor antagonists, dextromethorphan in the form of its hydrobromide salt is preferred for use herein due to its ready availability and its established use in over-the- counter medications where it functions as a cough suppressant. While dextrorphan and its pharmaceutically acceptable salts will also provide excellent results, it is not known to be in commercial manufacture at this time.
In addition to, or in place of, a blocker for the NMDA receptor, at least one nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation can also be used. Activation of the NMDA receptor, a subtype of excitatory amino acid receptors, induces a number of changes in the functional activity of nerve cells and, in particular, their capacity for excitability or inhibition in the presence of an addictive substance via an increase in intracellular Ca+ -I- concentration. The major consequences of NMDA receptor activation include the following sequences, or cascades, of events occurring within nerve cells: a) translocation and activation of protein kinases such as protein kinase C - phosphorylation of substrate proteins such as cytosolic enzymes, channel proteins, receptor proteins, etc. → changes in functional activity; b) initiation of early gene (c-fos, c-jun, zif-26$, etc.) expression by either increased intracellular Ca+ + or Ca+ + -activated protein kinases - expression of functional genes responsible for production of cellular enzymes (such as protein kinases), receptor proteins (such as the NMDA receptor), ion channel proteins (such as K+ , Na+ , Ca+ + channels), neuropeptides (such as dynorphin), etc. - changes in functional activity; c) Ca+ +/calmodulin (or other Ca+ + binding proteins) induced activation of enzymes and other cellular components - activation of
Ca+ +/calmodulin-protein kinase systems such as Ca+ +/calmodulin kinase II - autophosphorylation of enzymes (e.g., Ca-f- +/calmodulin kinase II) or other functional proteins - changes in functional activity; d) Ca+ +/calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase - production of nitric oxide → i) production of cyclic guanosine monophosphate via activation of guanosine cyclase resulting in activation of protein kinases and early gene expression; ii) direct protein modification such as enzymes, receptor and/or channel proteins; iii) lipid membrane modification and/or nucleic acid modification via scavenge of free radicals; iv) induction of neurotoxicity at higher nitric oxide levels; v) retrograde actions in adjacent neurons or glial cells such as facilitation of glutamate release/NMD A receptor activation and/or inhibition of post-synaptic NMDA receptors → changes in functional activity; e) interactions with the cyclic adenosine monophosphate/protein kinase A system, the phospholipase C-inositol triphosphate-Ca-r- +/diacylglycerol- protein kinase system, the phospholipase A2-arachidonic acid/prostanoids/ leukotrienes system - changes in functional activity induced by second messenger systems other than NMDA receptor/Ca+ +/Ca+ +-calmodulin/protein kinase systems; and, f) interactions with other excitatory amino acid receptor subtypes including non-NMDA receptors and metabotropic receptors as well as intracellular events subsequent to the activation of these excitatory amino acid receptor subtypes - changes in functional activity induced by the non-NMDA and metabotropic receptor activation.
A substance that blocks the NMDA receptor will effectively prevent all of the foregoing major intracellular sequences of events from taking place. However, even with activation of the NMDA receptor, it is still possible to alleviate pain in accordance with this invention by administering the substance P receptor antagonist and a nontoxic substance that blocks at least one of the foregoing major intra-cellular sequences of events brought about by activation of the NMDA receptor. Thus, e.g. , a substance that interferes with translocation and activation of protein kinase C or with calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase is also useful for the practice of this invention. Nontoxic substances that block a major intracellular consequence of
NMDA receptor activation and are therefore useful in the practice of the invention include inhibitors of protein kinase C, e.g., gangliosides such as ganglioside GM! (monosialoganglios.de) and ganglioside GTb (trisialoganglioside); amphipathic long chain bases such as sphingosine, N,N,N-trimethylsphingosine, sphinganine and psychosine; quinolyloxazole-2-ones such as 4-methyl-5-(3-quinolinyl)-2-(3H)-oxazolone and phenyl-5-(2-quinolinyl)-2-3(3H)-oxazolone; 1 ,4-bis-(amino-hydroxyalkylamino)- anthraquinones such as l,4-bis-(3-propylamino-2-hydroxypropylamino)-9,10 anthracenedione and 1 ,4-bis-(3-benzylamino-2-hydroxypropylamino)-9, 10 anthracenedione; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.
Additional nontoxic substances that block a major intracellular consequence of NMDA receptor activation and as such are useful in the practice of the invention include inhibitors of calmodulin such as the phenothiazines, in particular, chlorpromazine, chlorpromazine sulfoxide, prochlorperazine dimaleate, perphenazine, trifluoperazine, fluphenazine, fluphenazine enanthate, fluphenazine decanoate, thioridazine, mesoridazine besylate, piperacetazine, acetophenazine dimaleate, carphenazine dimaleate, butaperazine dimaleate and phenothiazine sulfoxide; naphthalenesulfonamides such as N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide, N-(6-aminohexyl)-5-chloro-2-naphthalenesulfonamide and N-(6-aminohexyl)-5-bromo- 2-naphthalenesulfonamide ; 4-substituted-4H , 6H-pyrrolo [ 1 , 2-a] [4,1] benzoxazepines such as l,3-dihydro-l-{l-[(4-methyl-4H,6H-pyrrolo[l,2-a][4,l] benzoxazepin-4- yl)methyl]-4-piperidinyl}-2H-benzimidazol-2-one; benzhydryls such as N- [2](diphenylmethylthioethyl]-2-(trifluoromethyl)-benzeneethanamine, N-[2-(bis(4- fluorophenyl)methylthio)- ethyl]-2-(trifluoromethyl)benzeneethanamine and N-[2-(bis(4- fluorophenyl)methylthio)ethyl]-3-(trifluoromemyl)beιιzene-ethanamine; tricyclic antidepressant drugs such as imipramine, 2-chloroimipramine and amitriptyline; penfluridol; haloperidol; pimozide; clozapine; calmidazolin; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.
Of the two groups of substance P receptor antagonist potentiators the nontoxic NMDA receptor antagonists are preferred and of these, dextromethorphan is preferred for the reasons previously stated. With regard to dosage levels, the substance P receptor antagonist must be present in an analgesically effective amount, e.g., at a level corresponding to the generally recommended adult human dosages for a particular substance P receptor antagonist, and the nontoxic NMDA receptor antagonist or substance that blocks a major intracellular consequence of NMDA activation must be present at a level that potentiates the therapeutic effectiveness of the substance P receptor antagonist. Given the wide variations in dosage level of the substance P receptor antagonist which depends to a large extent on the specific substance P receptor antagonist being administered, there can similarly be a wide variation in the dosage level of the nontoxic NMDA receptor antagonist or substance that blocks a major intracellular consequence of NMDA receptor activation. These amounts can be determined for a particular drug combination in accordance with this invention employing routine experimental testing. While the substance P receptor antagonist and nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation need not be administered together, they must both be present in the patient at effective levels at the same time. While it is within the scope of the invention to administer the substance P receptor antagonist and nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation separately, as a matter of convenience, it is preferred that they be coadministered as a single analgesic composition. All modes of administrations are contemplated, e.g. ^orally, rectally, parenterally, topically, or by intravenous, intramuscular, intrastemal or subcutaneous injection or in a form suitable by inhalation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy.
An analgesic composition containing the substance P receptor antagonist and nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation will ordinarily be formulated with one or more pharmaceutically acceptable ingredients in accordance with known and established practice. Thus, the analgesic composition can be formulated as a liquid, powder, elixir, injectable solution, etc. Formulations for oral use can be provided as tablets or hard capsules wherein the pharmacologically active ingredients are mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients are mixed with water or miscible solvents such as propylene glycol; PEG's and ethanol, or an oleaginous medium, e.g., peanut oil, liquid paraffin or olive oil.
For topical administration in the mouth, the analgesic composition herein can take the form of a buccal or sublingual tablet, drops or lozenges formulated in a known or conventional manner.
For topical administration, the analgesic composition of the invention can be formulated as a cream, gel, ointment or lotion or as a transdermal patch. Such composition can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening, gelling, emulsifying, stabilizing, dispersing, suspending and/or coloring agents.
The analgesic composition of the invention can also be formulated as a sustained release preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the analgesic composition can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The analgesic composition of the invention can be formulated for parenteral administration by injection, conveniently intravenous, intramuscular or subcutaneous injection, for example, by bolus injection or continuous intravenous infusion. Formulations for injection can be presented in unit dosage, e.g., in ampoules or in multi-dose containers, with an added preservative. The analgesic composition can take a variety of forms such as a suspension, solution or emulsion in an oily or aqueous vehicle and can contain one or more formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the analgesic composition can be provided in powder form for dissolution in a suitable vehicle, e.g. sterile pyrogen-free water, before administration.
The analgesic composition of the invention can also be formulated as a rectal composition, e.g., a suppository or retention enema containing conventional suppository bases such as cocoa butter or other glyceride(s).
For administration by inhalation, the analgesic composition is conveniently delivered in the form of an aerosol spray by means of a pressurized container or a nebulizer employing a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoro- ethane, heptafluoropropane, carbon dioxide, and the like. In the case of a pressurized aerosol delivery system, the dosage unit can be regulated by means of a metering valve.
Aqueous suspensions can include pharmaceutically acceptable excipients such as suspending agents, e.g., sodium carboxymethyl cellulose, methy lcellulose, hy droxypropy lmethy lcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, e.g, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g., polyoxyethylene sorbitan monoleate. The aqueous suspensions can also contain one or more preservatives, e.g., ethyl-or-n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate.
In addition to the substance P receptor antagonist and nontoxic NMDA receptor antagonist and/or substance that blocks a major intracellular consequence of NMDA receptor activation, the analgesic composition herein can contain at least one other pharmacologically active substance, e.g., a non-narcotic analgesic such as tramadol, acetaminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, zomepirac, and die like, or a narcotic analgesic such as codeine, oxycodone, dihydrocodeine, hydrocodone, levorphanol, morphine, and the like.
EXAMPLES 1-35 The following unit dosage forms are illustrative of the therapeutic drug combinations in accordance with the present invention: Nontoxic NMDA Receptor Additional Active
Example Substance P Receptor Antagonist (mg . Blocker (mg . Component (mg) 1 pyroglutamyl-phenylalanyl-N-methyl- dextromethorphan pheny lalanyl-[(R)-3-amino-2-oxo- 1 - hydrobromide (30) pyrrolidine-(S)-4-methyl-2-pentanoyl] methionine amide (25) [U.S. Patent No. 4,680,283] pyroglutamyl-phenylalanyl-N-methyl- dextromethorphan acetaminophen (325) phenylalanyl-[(R)-3-amino-2-oxo-l- hydrobromide (30) pyrrolidine-(S)-4-methyl-2-pentanoyl] methionine amide (25) [U.S. Patent No. 4,680,283] pyroglutamyl-phenylalanyl-N-methyl- dextrorphan phenylalanyl-[(R)-3-amino-2-oxo- 1 - hydrobromide (30) pyrrolidine-(S)-4-methyl-2-pentanoyl] methionine amide (25) [U.S. Patent No. 4,680,283]
Nontoxic NMDA Receptor Additional Active
Example Substance P Receptor Antagonist (mg. Blw er (mg) Component (mg) 4 2-[l-imino-2-(2-methoxyρhenyl)ethyl]-7,7- dextromethorphan diphenyl-4-perhydroisoindolone in its hydrobromide (30) (3aR,3aR) or (3aR,7aRS) forms (25) [U.S. Patent No. 5,102,667] 5 2-[l-imino-2-(2-methoxyphenyl)ethyl]-7,7- dextromethorphan ibuprofen (200) diphenyl-4-perhydroisoindolone in its hydrobromide (30) (3aR,3aR) or (3aR,7aRS) forms (25) [U.S. Patent No. 5,102,667] 6 2-[l-imino-2-(2-methoxyphenyl)ethyl]-7,7- dextrorphan diphenyl-4-perhydroisoindolone in its hydrobromide (30) (3aR,3aR) or (3aR,7aRS) forms (25) [U.S. Patent No. 5,102,667] 7 2-[l-imino-2-(2-methoxyphenyl)ethyI]-7,7- amantadine (30) diphenyl-4-perhydroisoindolone in its (3aR,3aR) or (3aR,7aRS) forms (25) [U.S. Patent No. 5,102,667] 8 2-[l-imino-2-(2-methoxyphenyl)ethyl]-7,7- memantine (30) diphenyl-4-perhydroisoindolone in its (3aR,3aR) or (3aR,7aRS) forms (25) [U.S. Patent No. 5,102,667] 9 cis-3-[(2-chlorophenyl)methylamino]-2- dextromethorphan benzhydrylquinuclidine (25) hydrobromide (30) [U.S. Patent No. 5,162,339]
10 cis-3-[(2-chlorophenyl)methylamino]-2- dextromethorphan acetaminophen (325) benzhydrylquinuclidine (25) hydrobromide (30)
[U.S. Patent No. 5,162,339]
11 cis-3-[(2-chlorophenyl)methylamino]-2- dextrorphan benzhydrylquinuclidine (25) hydrobromide (30)
[U.S. Patent No. 5,162,339]
12 cis-3-[(2-chlorophenyl)methylamino]-2- amantadine (30) benzhydrylquinuclidine (25)
[U.S. Patent No. 5,162,339]
13 cis-3-[(2-chlorophenyl)methylamino]-2- memantine (30) benzhydrylquinuclidine (25)
[U.S. Patent No. 5,162,339]
Nontoxic NMDA Receptor Additional Active
Example Substance P receptor antagonist (mg . Blocker (mg. Component (mg.
14 7-[(lS)-(l-meth xycarbonyl)-3-methylbutyl]- dextromethorphan 6-oxo-(5S)-l,7-diazaspiro[4.4]nonane-l- hydrobromide (30) carboxylic acid, phenylmethyl ester (25) [U.S. Patent No. 5, 166,136]
15 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyI]- dextromethorphan acetaminophen (325) 6-oxo-(5S)-l,7-diazaspiro[4.4]nonaπe-l- hydrobromide (30) carboxylic acid, phenylmethyl ester (25) [U.S. Patent No. 5,166,136]
16 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyl]- dextrorphan 6-oxo-(5S)-l ,7-diazaspiro[4.4]nonane-l- hydrobromide (30) carboxylic acid, phenylmethyl ester (25) [U.S. Patent No. 5, 166,136]
17 7-[( 1 S)-( 1 -methoxycarbonyl)-3-methy lbutyl]- amantadine (30) 6-oxo-(5S)-l,7-diazaspiro[4.4]nonane-l- carboxylic acid, phenylmethyl ester (25) [U.S. Patent No. 5, 166,136]
18 7- [( 1 S)-( 1 -methoxycarbony l)-3-methy lbutyl]- memantine (30) 6-oxo-(5S)-l,7-diazaspiro[4.4]nonane-l- carboxylic acid, phenylmethyl ester (25) [U.S. Patent No. 5, 166,136]
19 cis-3-(2-methoxybenzylamino)-2- dextromethorphan phenylpiperidine (25) hydrobromide (30)
[U.S. Patent No. 5,232,929] 20 cis-3-(2-methoxyber__ylamino)-2- dextromethorphan aspirin (325) phenylpiperidine (25) hydrobromide (30) [U.S. Patent No. 5,232,929]
21 cis-3-(2-methoxybenzylamino)-2- dextrorphan phenylpiperidine (25) hydrobromide (30) [U.S. Patent No. 5,232,929]
22 cis-3-(2-methoxybenzylamino)-2- amantadine (30) phenylpiperidine (25) [U.S. Patent No. 5,232,929]
23 cis-3-(2-methoxybe___ylamino)-2- memantine (30) phenylpiperidine (25) [U.S. Patent No. 5,232,929]
24 N-[4-[l-(fluorobenzyl)-4-piperidinyl]-2- dextromethorphan (3,4-dichlorophenyl)-butyl]-2,4- hydrobromide (30) dichlorobenzamide hydrochloride (25) [U.S. Patent No. 5,300,648 and 5,446,052] Nontoxic NMDA Receptor Additional Active
Example Substance P receptor antagonist (mg. Blocker (mg. Component (m .
25 N-[4-[l-(fluoro6enzyl)-4-piperidinyl]-2- dextromethorphan acetaminophen (325) (3,4-dichlorophenyl)-butyl]-2,4- hydrobromide (30) dichlorobenzamide hydrochloride (25) [U.S. Patent No. 5,300,648 and 5,446,052]
26 N-[4-[l-(fluorobenzyl)-4-piperidinyl]-2- dextrorphan (3,4-dichlorophenyl)-butyl]-2,4- hydrobromide (30) dichlorobenzamide hydrochloride (25) [U.S. Patent No. 5,300,648 and 5,446,052]
27 N-[4-[l-(fluorobenzyl)-4-piperidinyl]-2- amantadine (30) (3,4-dichlorophenyl)-butyl]-2,4- dichlorobenzamide hydrochloride (25) [U.S. Patent No. 5,300,648 and 5,446,052]
28 N-[4-[l-(fluorobenzyl)-4-piperidinyl]-2- memantine (30) (3,4-dichlorophenyl)-butyl]-2,4- dichlorobenzamide hydrochloride (25) [U.S. Patent No. 5,300,648 and 5,446,052]
29 3-[2-(4-Benzy lpiperidin- 1 -y l)ethyl]-3- dextromethorphan (3,4-dichlorophenyl)-l-phenylacetyl- hydrobromide (30) piperidine hydrochloride (25) [U.S. Patent No. 5,340,822]
30 3-[2-(4-Benzylpiperidin-l-yl)ethyl]-3- dextromethorphan ibuprofen (200) (3 ,4-dichloropheny 1)- 1 -phenylacetyl- hydrobromide (30) piperidine hydrochloride (25)
[U.S. Patent No. 5,340,822]
31 3-[2-(4-Benzylpiperidin- 1 -y l)ethyl]-3- dextrorphan (3,4-dichlorophenyI)-l-phenylacetyl- hydrobromide (30) piperidine hydrochloride (25)
[U.S. Patent No. 5,340,822]
32 N-[4-(4-N'-Acetylanilino-l-piperidinyl)- dextromethorphan 2-(3,4-dichlorophenyl)butyl]-N- hydrobromide (30) methylbenzamide (25) [U.S. Patent No. 5,411,971]
33 8-(diphenylmethyl)-N-((2-methoxyphenyl) dextromethorphan methyl))-9-azatricyclo[4.3.1.04 9] hydrobromide (30) decan-7-amine (25) [U.S. Patent No. 5,422,354] Nontoxic NMDA Receptor Additional Active
Example Substance P receptor antagonist (mg . Blocker (m . Component .mg) 34 trans-2-phenyl-N-(2-methoxyphenyl) dextromethorphan methyl)-l-azabicyclo[2.2.2]octan-3- hydrobromide (30) amine (25) [U.S. Patent No. 5,451,586] 35 {l-[4-(lH-tetrazol-5-yl)butyl]indol-3-yl} dextromethorphan carbonyl-Hyp-Thn-Nmebzl (25) hydrobromide (30) [U.S. Patent No. 5,561,113]
In each of these dosage units, the nontoxic NMDA receptor antagonist dextromethorphan hydrobromide significantly potentiates the analgesic activity of the substance P receptor antagonist.

Claims

WHAT IS CLAIMED IS:
1. An analgesic composition which comprises (a) an analgesically effective amount of at least one substance P receptor antagonist and (b) a substance P receptor antagonist-potentiating amount of at least one substance P receptor antagonist potentiator selected from the group consisting of N-methyl-D-aspartate receptor nontoxic antagonist and nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation.
2. The analgesic composition of Claim 1 wherein the substance P receptor antagonist is selected from the group consisting of a substance P analog, undecapeptide, hexapeptide amide, di-(D-tryptophyl and/or tetra- hydropyridoindolylcarbonyl)-containing peptide amide, isoindolone, quinuclidine, peptide, spirolactam, 3-aminopiperidine and related nitrogen containing heterocycle, dialkylenepiperidino, 1-acylpiperidine, cyclic dimeric dipeptide derivative, polycyclic amine, azole-fused peptide, N-alkylenepiperidino, 3-amino-2-arylquinuclidine, isoquinolinyl, prolyl endopeptidase inhibitor compound, pseudopeptide, piperidine, chromone compound, perhydroisoindole, substituted pyrrolidin-3-yl-alkyl-piperidine, fused ring analog of nitrogen containing heterocycle, N-alkyl quinuclidinium salt, 1- azabicyclo[3.2.2]nonan-3-amine, N-N-diacyl-piperazine, substituted 3-amino- quinuclidine, azanorbornane compound, fluoroalkoxybenzylamino derivative of nitrogen containing heterocycle, fused tricyclic, aromatic compound, fused tricyclic nitrogen containing heterocycle, acyclic ethylenediamine, perhydroisoindole, substituted benzylamino nitrogen containing non-aromatic heterocycle, substituted benzylaminoquinuclidine, N-benzoyl-4-oxy/thio-2-substituted piperidine, aromatic amine, azabicy clic, thiopyranipyrrole and azacyclic.
3. The analgesic composition of Claim 2 wherein the substance P analog is selected from the group consisting of L-amino acid sequence G-L-M-NH2, O- G-L-M-NH2, F-G-L-M-NH2, pyroglutamyl-ohenylalanyl-phenylalanyl-[(R)-3-amino-2- oxo-l-pyrrolidine-(S)-4-methyl-2-pentanoyl]methionine amide and pyroglutamyl- phenylalanyl-N-methyl-phenylalanyl-[(R)-3-amino-2-oxo-l-pyrrolidine-(S)-4-methyl-2- pentanoyl]methionine amide, undecapeptide is selected from the group consisting of L- arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutammyl-L-glutaminyl-L-phenylalanyl-L-glycyl- L-leucyl-L-methionine amide, [D-Phe5, D-Trp7, D-Trp9, Leun]-SP, [Glp5, D-Trp7, D- Trp9, Thrn]-SP5.n, and [D-Arg1, D-Tφ7, D-Trp9, Leuu]-SP, hexapeptide amide is selected from the group consisting of Hpro-Phe-Phe-DAla-Leu-MetNH2, HPro-Phe- MePhe-Gly-Leu-MetNH2 and HPro-Phe-Phe-Gly-DLeu-MetNH2, di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amide is selected from the group consisting of H-trp-Phe-trp-Leu-Met-NH2, Hpro-trp-Phe-trp-Leu-Phe-NH2 and H-tpi-Phe-trp-Leu-Met-NH2, isoindolone is selected from the group consisting of 2-[l- imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4-perhydroisoindolone in its (3aR,7aR) or (3aR,7aRS) forms, 7,7-diphenyl-2-[2-(2-dimethylaminophenyl)acetyl]-4-perhydro- isoindolone in its (3aR,7aR) or (3aRS,7aRS) forms, 7,7-diphenyl-2-[(R)-2-(2-methoxy- phenyl)propionyl]-4-perhydroisoindolone in its (3aR,7aR) or (3aRS,7aRS) forms, diphenyl-7,7[dimethylamino-2 phenyl)-2 acetyl]-2 perhydroisoindolone-4, diphenyl- 7,7[methoxy-2 phenyl)-2 propionyl-(R)]-2 perhydroisoindolone-4 and [(5)-carboxy benzylimino-1 (methoxy-2 phenyl)-2 ethyl]-2 diphenyl-7,7 perhydro-isoindolone-4, quinuclidine is selected from the group consisting of cis-3-[(2-chlorophenyl)- methylamino]-2-benzhydrylquinuclidine, cis-3-[(2-trifluoro-methylphenyl)methyl- amino] -2-benzhydrylquinuclidine , cis-3 -[(2-methoxy-pheny l)methy lamino] -2-benz- hydrylquinuclidine, 8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl))-9-azatricyclo- [4.3.1.04'9]decan-7-amine, 8-(diphenylmethyl)-N-(phenylmethyl)-9-azatricyclo- [4.3.1.04'9]decan-7-amine , 8-(dipheny lmethy l)-N-((2-chlorophenyl)methyl))-9- azatricyclo[4.3.1.04'9]decan-7-amine, (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl- 2-dipheny lmethyl- 1 -azabicy clo [2.2.2] octan-3-amine , (2S , 3 S)-N-(5-ethy 1-2-methoxy- pheny l)methy 1-2-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octan-3 -amine , (2S , 3 S)-N-(5 - isopropy 1-2-methoxypheny l)methy 1-2-dipheny lmethy 1- 1 -azabicy clo [2,2.2] octan-3 -amine , (3R,4S,5S,6S)-N-carbamoylmemyl-5-(5-isopropyl-2-memoxybenzyl-amino)-6- dipheny lmethyl- 1 -azabicy clo [2.2.2] octane-3 -carboxamide , (3R,4S , 5S , 6S)-N-carboxy- methy l-5-(5-isopropyl-2-methoxybenzy lamino)-6-dipheny lmethy 1- 1 -azabicy clo [2.2.2]- octane-3-carboxamide and (3R,4S,5S,6S)-3-(2-carbamoylpyrrolidin-l-yl)carbonyl-5-(5- isopropyl-2-methoxybenzy lamino)-6-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octane , the peptide is selected from the group consisting of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe- Gly-Leuψ[CH2-NH]Leu-NH2, H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trpf[CH2- NH]Leu-Nle-NH2, H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trpψ[CH2-NH]Phe-D-Trp-Leu- Nle-NH2, Boc-Phe-(p-CH3)-OH, Boc-Phe-(p-F)-OH, Boc-Gin-D-Trp(CHO)-Phe-NMe- Bzl, Boc-Thr-D-Trp(CHO)-Phe-NMeBzl, Boc-Glu(NMe2)-D-Trp(CHO)-Phe-NMeBzl, cyclo(Gln-Trp-Phe-(R)Gly-[ANC-2]Leu-Met, cyclo(Gln-Npa-Phe-(R)Gly[ANC-2]Leu- Met and cyclo(Gln-Trp-Phe-Gly-Leu-Met), spirolactam is selected from the group consisting of 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyl]-6-oxo-(5S)-l ,7-diaza- spiro[4.4]nonane-l-carboxylic acid, phenylmethyl ester, 7-[(lS)-(l-met__oxycarbonyl)-3- methylbutyl]-6-oxo-(5S)-l ,7-diazaspiro[4.4]nonane-l-carboxylic acid phenylmethyl ester, 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyl]-6-oxo-(5S)-l ,7-diazaspiro-
[4.4]nonane-l-carboxylic acid and (l,l-dimet__yl)ethyl ester, 3-aminopiperidine and related nitrogen containing heterocycle is selected from the group consisting of cis-3-(2- methoxybenzylamino)-2-phenylpiperidine, cis-l-allyl-3-(2-methoxybenzylamino)-2- phenylpiperidine, cis-l-ethyl-3-(2-methoxybenzylamino)-2-phenylpiperidine, cis-3-(2- c orober_zylamino)-2-phenylpiperidine, cis-3-(2-trifluoromethylbenzylamino)-2- pheny -piperidine, cis-3-(2-methoxybenzylamino)-2-(2-fluorophenyl)-piperidine, (2S ,3S)- 3-(4,5-difluoro-2-memoxybenzyl)amino-2-phenyl-piperidine, (2S,3S)-3-(2- cyclopentyloxy-5-methoxybenzyl)amino-2-phenylpiperidine and (2S,3S)-3-(5-sec-butyl- 2-methoxybenzyl)amino-2-phenyl-piperidine, dialkylenepiperidino is selected from the group consisting of N_-[4-(l-benzyl-4-piperidinyl)-2-(3,4-dichlorophenyl)-butyl]-4- fluoronaphtalene carboxamide hydrochloride, N-[4-[l-(fluorobenzyl)-4-piperidinyl-2- (3,4-dichlorophenyl)-butyl]-2,4-dichlorobenzamide hydrochloride, N-methyl-N-[4-(l- benzyl-4-piperidinyl)-2(3,4-dichlorophenyl)-butyl]3-isopropoxyphenylacetamide hydrochloride, chlorohydrate of N-[{4-[l-benzyl-piperidin-4-yl]-2-(3,4-dichloro- phenyl)} -butyl] -4-fluoronaphtalenecarboxamide, chlorohydrate of N-[{2-(3,4-dichloro- phenyl)-4-[l-(4-fluorobenzyl)-piperidin-4-yl]}-butyl]-2,4-dichlorobenzamide and chlorohydrate of N-methyl-N-{{4-{l-benzyl-piperidine-4-yl]-2-(3,4-dichlorophenyl)}- butyl]-3-isopropoxyphenylacetamide, the 1-acylpiperidine is selected from the group consisting of (2R,4S) and (2R,4R)-2-benzyl-l-(3,5-dimethylbenzoyl)-N-(2-phenethyl)-4- piperidinamine hydrochloride, (2R*,4S*)-2-benzyl-l-(2-naphthoyl)-N-(4-quinolyl- methyl)-4-piperidinamine, (2R*,4S*)-2-be_izyl-2-(3-trifluoro-methylbenzoyl)-N-(4- quinoly lmethy l)-4-piper idinamine , (2R* , 4S *)-2-benzy 1- 1 -(2-naphthoy l)-N-(4-chinoly 1- methyl)-4-piperidinamin, (2R*,4S*)-2-benzyl-l-(3-trifluoromethylbenzoyl)-N-(4- chinolylmethyl)-4-piperidinamin and (2R*,4S*)-2-benzyl-l-(3 ,5-bis-(trifluoromethyl)- benzoyl)-N-(4-chinolylmethyl)-4-piperidinamin, polycyclic amine is selected from the group consisting of 4-[2-(4-benzylpiperidin-l-yl)ethyl]-4-(3-methylphenyl)-l-(3- chlorophenyl)acetylpiperidine hydrochloride, 3-[2-(4-Benzylpiperidin-l-yl)ethyl]-3-(3,4- dichlorophenyl)-l -pheny lacetylpiperidine hydrochloride, 5-[2-(4-benzylpiperidin-l- yl)ethyl]-5-(3,4-dichlorophenyl)-l-benzylpiperidinone hydrochloride, chlorhydrate of 5- [2-(4-benzyl- 1 -piperidinyl)ethyl] -5-(3 ,4-dichlorophenyl)- 1 -benzyl-piperidinone, chlorohydrate of 3 - [2-(4-benzy 1- 1 -piper idinyl)ethy 1] -3 -(3 ,4-dichloropheny 1)- 1 -pheny 1- acety .piperidine, chlorohydrate of 3-[2-(4-benzyl-l-piperidinyl)ethyl]-3-(3,4- dichlorophenyl)-l-(3-isopropoxy-phenyl)acetylazepine, the N-alkylenepiperidino is selected from the group consisting of N-[2-(3,4-dichlorophenyl)-4-(4-(2-pyridylthio)-l- piperidinyl)butyl] -2 ,4-dichlorobenzamide , N-[4-(4-N ' -acetylanilino- l-piperidinyl)-2- (3,4-dichlorophenyl)butyl]-N-methylbenzamide and N-[4-(l -methy 1-2-imidazoly l)-4- thio-l-piperidinyl)-2-naphthylbutyl]-2,4-dimethoxybenzamide, 3-amino-2-aryl- quinuclidine is selected from the group consisting of trans-2-phenyl-N-(2-methoxy- pheny l)methy 1)- 1 -azabicy clo [2.2.2] octan-3-amine , cis-2-pheny l-N-(pheny lmethyl)- 1 - azabicy clo- [2.2.2] octan-3-amine and 2-( 1 -naphthy l)-N-((2-methoxypheny l)methyl)- 1 - azabicyclo[2.2.2]octan-3-amine, isoquinolinyl is selected from the group consisting of N-[(6-chloro-l,2-dihydro-2-methyl-l-oxo-4-phenylisoquinolin-3-yl)methyl]-N'- (3isopropoxyphenyl)urea, N-[(l,2-dihydro-2,6,7-trimethyl-l-oxo-4-phenylisoquinolin-3- yl)methyl]-N '-(3 -methy lpheny l)urea and N-[(l,2-dihydro-2-methyl-l-oxo-4-phenyl- isoquinolin-3yl)methyl]-N'-(3-methylphenyl)urea, prolyl endopeptidase inhibitor compound is selected from the group consisting of (S)-2-[[(S)-2-(acetoxyacetyl)-l- pyrrolidiny 1] carbony 1] -N-(pheny lmethy 1)- 1 -pyrrolidinecarboxam.de , (S)-2- [ [(S)-2- (hydroxyacetyl)-l-pyrrolidinyl]carbonyl]-N-phenylmethyl-l-pyrrolidinecarboxamide and (S)-2-[[(S)-2- [(benzoyloxy acetyl)- 1 -pyrrolidinyl] carbony 1] -N-(pheny lmethyl)- 1 - pyrrolidinecarboxamide, pseudopeptide is selected from the group consisting of {l-[4- (lH-tetrazol-5-yl)butyl]indol-3-yl}carbonyl-Hyp-Nal-NMeBzl, {l-[4-(lH-tetrazol-5- yl)butyl]indol-3-yl} carbony 1-Hyp-Tna-NMeBzl and { l-[4-(lH-tetrazol-5-yl)butyl]indol- 3-yl}carbonyl-Hyp-Thn-NMeBzl, piperidine is selected from the group consisting of (2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3trifluoromethoxyphenyl)piperidine, (2S , 3 S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-pheny 1-piperidine , (2S , 3S)- 3-(2-ethoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine, l-[2-(5-fluoro-lH- indol-3-yl)ethyl]-4-[((2-methyl)phenylsulfιnyl)methyl]-4-piperidinol, l-[2-(5-fluoro-lH- indol-3-yl)ethyl]-4-[((4-methyl)phenylsulf_nyl)methyl]-4-piperidinol and l-[2-(5-Fluoro- lH-indol-3-yl)ethyl]-4-[(phenylsulfϊnyl)methyl]-4-piperidinol, chromone compound is selected from the group consisting of (2R,4S)-N-[l-(3,5-bistrifluoromethylbenzoyl)-2- (4-chlorobenzy l)piperidin-4-yl] -4-oxo-4H- 1 -benzopyrene-2-carboxamide , (2R,4S)-N- [ 1 - (3,5-bistrifluormethylbenzoyl)-2-benzylpiperidin-4-yl]-4-oxo-4H-l-benzopyrene-2- carboxamide and (2R,4S)-N-[l-(3 ,5-bistrifluoromethylbenzoyl)-2-(4-chloro-benzyl)- piperidin-4-yl] -6-fluoro-4-oxo-4H- 1 -benzopy rene-2-carboxamide , perhydroisoindole is selected from the group consisting of {{[(pyrrolidinyl-l)-3 propoxy-2]phenyl}acetyl}-2 diphenyl-4,4 fluoro-7 perhydroisoindole, diphenyl-4,4 fluoro-7 [(methoxy-2 phenyl)-2 propionyl-(S)]-2 perhydroisoindole, [(dimethylamino-3 propoxy)-2 phenyl]acetyl-2 diphenyl-4,4 fluoro-7 perhydroisoindole, 7,7-dimethyl-4-(2-methoxyphenyl)-2-[2-(S)-(2- methoxyphenyl)propionyl]-4,5-perhydroisoindolediol, 4-(2-methoxyphenyl)-2-[2-(S)-(2- methoxyphenyl)proponyl]-5-methyl-4-perhydro-isoindolol, 2-[2-(S)-(2-hydroxy- pheny l)propiony 1] -4-(2-methoxypheny l)-6-methy 1-4-perhydroisoindolol , dipheny 1-7 , 7 (methoxy-2 phenyl)-4[(methoxy-2 phenyl)-2 propionyl]-2 perhydroisoindolol-4, diphenyl-7,7 (methoxy-2 phenyl)-4 [(methoxy-2 phenyl)-2 propionyl]-2 perhydroiso- indolediol-4,5 and diphenyl-7,7 (methoxy-2 pheny l)-4 [(hydroxy -2 pheny l)-2 acetyl] -2 perhydroisoindolol-4, substituted pyrrolidin-3yl-alkyl-piperidine is selected from the group consisting of (+)-or(-)-l-(2-[3-(3,4-dichloro-phenyl)-l-[2-(2-methoxy-phenyl)- acetyl]-pyrrolidin-3-yl]-ethyl)-4-phenyl-piperidine-4-carboxylic acid amide, (+)-or(-)-l- [2- [3 -(3 , 4-dichloro-phenyl)- 1 (2 , 6-dimethoxy-benzoy l)-pyrrolidin-3 -y 1] -ethyl] -4-phenyl- piperidine-4-carboxylic acid amide and (+)-or(-)-l-[2-[3-(3,4-dichloro-phenyl)-l(3,4,5- trimethoxy-benzoyl)-pyrrolidin-3-yl]-ethyl]-4-phenyl-piperidine-4-carboxylic acid amide, fused ring analog of nitrogen containing heterocycle is selected from the group consisting of [l ,3α,4α,5 ] -4-(2-methoxybenzyl)amino-3 -pheny 1-2-azabicy clo- [3.3.0] octane, 4-(2-methoxybenzyl)amino-3-phenyl-2-azabicyclo[4.4.0]decane and 4-(2- methoxybenzyl)amino-4-benzhydryl-3-azabicyclo[4.1.0]heptane, N-alkyl quinuclidinium salt is selected from the group consisting of (2S,3S)-cis-l -methy l-2-(dipheny lmethy 1)-N- ((2-methoxyphenyl)methyl)-l-azabicyclo[2.2.2]octan-3-amine iodide, (2S,3S)-cis-l-(4- carbethoxybutyl)-2-(dipheny lmethy l)-N-((2-methoxypheny l)-methyl- 1 - azabicyclo[2.2.2]octan-3-amine iodide and (2S,3S)-cis-l-(4-carboethoxy-phenylmethyl)- 2-(dipheny lmethy l)-N-((2-methoxypheny l)methy 1)- 1 -azabicy clo [2.2.2] -octan-3 -amine iodide, 1 -azabicy clo [3.2.2] nonan-3-amine is selected from the group consisting of 2- (diphenylmemyl)-N-((2-memoxyphenyl)methyl)-azabicyclo[3.2.2]-nonan-3-amine, 2- (diphenylmethyl)-N-((2-chlorophenyl)methyl)-l-azabicyclo[3.2.2]-nonan-3-amine and 2- (dipheny_memyl)-N-((2,4-dimemoxyphenyl)memyl)-l-azabicyclo-[3.2.2]nonan-3-a_τ_ine, N,N-diacyl-piperazine is selected from the group consisting of l,4-bis(N,N-diphenyl- carbamoyl)piperazine-2-carboxylic acid, 1 ,4-bis(N,N-diphenyl-carbamoyl)-2-methyl- piper azine and 1 -(N , N-di-n-penty lcarbamoy l)-4-(N , N-dipheny 1-carbamoy l)piperazine-2- carboxylic acid, substituted 3-aminoquinuclidine is selected from the group consisting of (3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoyxbenzyl-amino)-6-diphenylmethyl-l- azabicyclo[2.2.2]octane-3-carboxamide, (3R,4S,5S,6S)-5-(5-isopropyl-2- methoxybenzylamino)-6-diphenylmethyl-l-azabicyclo[2.2.2]octane-3-carboxylic acid and (3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-l- azabicyclo[2.2.2]octane-3-carboxylic acid, azanorbornane compound is selected from the group consisting of (lSR,2SR,3SR,4RS)-l-aza-2-diρhenylmethyl-3-[(2- methoxyphenyl)methylamino]bicyclo[2.2.1]heptane, (lSR,2SR,3SR,4RS)-l-aza-2- dipheny lmethy 1-3 - [(2-methoxy-5-( 1 , 1 -dimethylethyl)pheny l)methy lamino] -bicy clo- [2.2. l]heρtane and (lSR,2SR,3SR,4RS)-l-aza-2-diphenylmethyl-3-[(2-methoxy-5- trifluoromethoxyphenyl)methylamino]bicyclo[2.2.1]heptane, fluoroalkoxybenzylamino derivative of nitrogen containing heterocycle is selected from the group consisting of (2S,3S)-2-phenyl-3-[2-(2,2,2-trifluoroethoxy)-benzyl]aminopiperidine, 2-(diphenyl- methyl)-N-((2-difluoromethoxy)phenyl)methyl-l-azabicyclo[2.2.2]octan-3-amine and (2S,3S)-N-(2-methoxy-5-trifluoro-methoxyphenyl)methyl-2-diphenylmethyl-l-aza- bicyclo[2.2.2]octane-3-amine, fused tricyclic is selected from the group consisting of 1- (5H-dibenzo[a.d]cyclohepten-5-yl)-2-)3,5-dimemylbenzyloxy)ethylamine, N-acetamido- l-(5H-dibenzo[a,d]cyclohepten-5-yl)-2-(3,5-dimethylbenzyloxy)ethylamine and 1- (10,1 l-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)-2-(3 ,5-dimethylbenzyl- oxy)ethylamine, aromatic compound is selected from the group consisting of 2- ammonium-l-((3,5-dimethylphenyl)-methyloxy)-3,3-diphenylpropane, 2-dimethyl- ammonium-l-((3,5-dimethylphenyl)-methyloxy)-3,3-diphenylpropane, 2-t-butoxy- carbonylamino-3,3-diphenylpropanoyl-(2-methoxyphenyl)methylamide, L-l-((3,5- bis(trifluoromethyl)phenyl)methyloxy)-2-(t-butoxycarbonylamino)-2-phenylethane, 1- ((3,5-dimethylphenyl)methyloxy)-2(S)-2-(((carbomethoxy)methyl)amino)-2-phenyl- ethane, (2S)-2-(((carboxarm^o)memyl)-ammomum-l-((3,5-dimethylphenyl)methyloxy)- 2-phenylethane, 3,5-dimethylbenzyl 2-(l , l-dimethylethoxycarbonylamino)-3-(3- indolyl)propionate, 2-methoxybenzyl 2-(l , l-dimethylethoxycarbonylamino)-3-(3- indolyl)propionate, 3,5-dimethylbenzyl 2-acetamido-3-(3-indolyl)propionate, 3,5- dimethylbenzyl 2-cyclohexanecarboxamido-3-(3-indolyl)propionate, 2-ammonium-3,3- diphenylpropanoyl-(2-methoxyphenyl) methylamide, (3 ,5-dimethylphenyl)methyl-2- ammonium-3,3-diphenylpropanoate and 2-methylammonium-l-((3,5-dimethylphenyl)- methyloxy)-3,3-diphenylpropane, fused tricyclic nitrogen containing heterocycle is selected from the group consisting of ( + )-cis-9-dipheny lmethy 1-N- ((2-methoxyphenyl)- methyl)-10-azatricyclo[4.4.1.05,7]undecan-8-amine (+)-cis-9-d.phenylmetl.yl-N-(2- methoxy-5-chlorophenyl)-10-azatricyclo[4.4. l.O^undecan-δ-amine and (±}-cis-9- diphenylmethyl-N-(2-trifluoromethoxyphenyl)-10-azatricyclo[4.4.1.05,7]undecan-8- amine, acyclic ethylenediamine is selected from the group consisting of 1-amino-l- phenyl-2-[(2-methoxy)phenylmethylamino]propane, (IR' ,2S')-l-cyclohexylamino-l- pheny 1-2- [(2-methoxy )-pheny lmethy lamino]propane and 1 -N-cyclohexy 1- 1 -pheny 1-2-N ' - [(2-methoxy-5-trifluoromethoxyphenyl)methyl]-l,2-ethanediamine, substituted benzylamino nitrogen containing non-aromatic heterocycle is selected from the group consisting of (2S,3S)-N-(2-methoxy-5-methylsulfonylphenyl)-methyl-2-diphenylmethyl- l-azabicyclo-[2.2.2]octan-3-amine, (2S,3S)-N-(2-methoxy-5-methylthiophenyl)methyl- 2-diphenylmethyl-l-azabicyclo[2.2.2]octan-3-amine and (2S,3S)-N-(2-methoxy-5- dimethylaminopheny l)methy 1-2-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octan-3 -amine , substituted benzylaminoquinuclidine is selected from the group consisting of (2S,3S)-N- (5-isopropeny 1-2-methoxypheny l)methyl-2-dipheny lmethy 1- 1 -azabicy clo [2.2.2] octan-3- amine , (2S , 3S)-N-(2-methoxy-5-vinylphenyl)methyl-2-dipheny lmethyl- 1 -azabicyclo- [2.2.2]octan-3-amine and (2S,3S)-N-(2-methoxy-4,5-dimethylphenyl)methyl-2- diphenylmethyl-l-azabicyclo[2.2.2]octan-3-amine, N-benzoyl-4-oxy/thio-2-substituted piperidine is selected from the group consisting of (2R*,4S*)-2-benzyl-l-(3,5- bistrifluoromethylbenzoyl-4-(4-quinolylmethoxy)-piperidine, (2R*,4S*)-quinoline-3- carboxylic acid[2-benzy 1- 1 -(3 , 5-bistrifluoromethy lbenzoyl)-piperidin-4-yl] ester and (2R* ,4S*)-2-benzyl- 1 -(3 ,5-bistrifluoromethylbenzoyl-4-(3-quinolylmethoxy)-piperidine , aromatic amine is selected from the group consisting of N[(benzyl-4-piperidinyl-l)- 4(dichloro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide, N[(benzyl-4 piperidinyl-1)- 4(difluoro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide and N[(benzyl-4 piperidinyl-1)- 4(dichloro-3,4 phenyl)-2 butyl] fluoro-4 naphthalene-1 carboxamide, azabicyclic is selected from the group consisting of trans-3-[3,5-bis(trifluoromethyl)benzyloxy]-2- (dipheny lmethy 1)-1 -azabicy clo [2.2.2] octane, trans-3-(3 ,5-dimethoxybenzyloxy)-2- (diphenylmethyl)-l-azabicyclo[2.2.2]octane, trans-2-(diphenylmethyl)-3-(3-phenoxy- benzyloxy)-l-azabicyclo[2.2.2]octane, 3-[(3,5-dimethylphenyl)methyloxy]-2-(l,2- diphenylethyl)-l-azabicyclo[2.2.2]octane and 3-[(3,5-bistrifluoromethylphenyl)- methyloxy]-2-(l,2-diphenylethyl)-l-azabicyclo[2.2.2]octane, 3-[(3,5-bistri- fluoromethy lpheny l)methyloxy]-2-[ 1 -( 1 -(4-methoxyphenyl)-2-pheny l)ethyl] - 1 -azabicy clo [2.2.2] octane, thiopyranipyrrole is selected from the group consisting of {[(dimethylamino-3 propoxy-2) phenyl]acetyl)-6 diphenyl-4,4-oxyde-l perhydro- thiopyrano[2,3-c]pyrrole, {[(pyrrolidinyl-l)-3 propoxy-2] phenyl} acetyl}-6 diphenyl- 4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole and [{methoxy-2 phenyl)-2 propionyl- (S)]-6 diphenyl-4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole and the azabicyclic is selected from the group consisting of cis-2-(diphenylmethyl-3-(3,5-dimethyl- benzyloxy)-l-methylpyrrolidine, cis-3-((3,5-dimethylphenyl)methyloxy)-2-phenyl- piperidine and cis-3-((3 ,5-dimethylphenyl)methyloxy- l-methyl-2-phenylpiperidine.
4. .The analgesic composition of Claim 1 containing a therapeutically effective amount of at least one other pharmacologically active substance (c).
5. The analgesic composition of Claim 4 wherein the pharmacologically active substance (c) is selected from the group consisting of non- narcotic analgesics and narcotic analgesics.
6. The analgesic composition of Claim 5 wherein the non-narcotic analgesic is selected from the group consisting of tramadol, acetaminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac.
7. The analgesic composition of Claim 5 wherein the narcotic analgesic is selected from the group consisting of codeine, dihydrocodeine, heroin, hydrocodone, levorphanol, morphine and oxycodone.
8. The analgesic composition of Claim 1 wherein the nontoxic N- methyl-D-aspartate receptor antagonist is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salts thereof.
9. The analgesic composition of Claim 2 wherein the nontoxic N- methyl-D-aspartate receptor antagonist is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salts thereof.
10. The analgesic composition of Claim 1 wherein (a) and (b) are present in sustained release dosage form.
11. A method of treating pain which comprises administering to a mammal exhibiting pain (a) an analgesically effective amount of at least one substance P receptor antagonisl and (b) a substance P receptor antagonist-potentiating amount of at least one substance P receptor antagonist potentiator selected from the group consisting of nontoxic N-methyl-D-aspartate receptor antagonist and nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation.
12. The method of Claim 11 wherein the substance P receptor antagonist is selected from the group consisting of a substance P analog, undecapeptide, hexapeptide amide, di-(D-tryptophyl and/or tetra-hydropyridoindolylcarbonyl)- containing peptide amide, isoindolone, quinuclidine, peptide, spirolactam, 3- aminopiperidine and related nitrogen containing heterocycle, dialkylenepiperidino, 1- acylpiperidine, cyclic dimeric dipeptide derivative, polycyclic amine, azole-fused peptide, N-alkylenepiperidino, 3-amino-2-arylquinuclidine, isoquinolinyl, prolyl endopeptidase inhibitor compound, pseudopeptide, piperidine, chromone compound, perhydroisoindole, substituted pyrrolidin-3-yl-alkyl-piperidine, fused ring analog of nitrogen containing heterocycle, N-alkyl quinuclidinium salt, 1 -azabicy clo [3.2.2] nonan- 3-amine, N-N-diacyl-piperazine, substituted 3-aminoquinuclidine, azanorbornane compound, fluoroalkoxybenzylamino derivative of nitrogen containing heterocycle, fused tricyclic, aromatic compound, fused tricyclic nitrogen containing heterocycle, acyclic ethylenediamine, perhydroisoindole, substituted benzylamino nitrogen containing non-aromatic heterocycle, substituted benzylaminoquinuclidine, N-benzoyl- 4-oxy/thio-2-substituted piperidine, aromatic amine, azabicyclic, thiopyranipyrrole and azacyclic.
13. The method of Claim 12 wherein the substance P analog is selected from the group consisting of L-amino acid sequence G-L-M-NH2, O-G-L-M- NH2, F-G-L-M-NH2, pyroglutamyl-ohenylalanyl-phenylalanyl-[(R)-3-amino-2-oxo-l- pyrrolidine-(S)-4-methyl-2-pentanoyl]methionine amide and pyroglutamyl-phenylalanyl- N-methyl-phenylalanyl-[(R)-3-amino-2-oxo-l-pyrrolidine-(S)-4-methyl-2- pentanoyl]methionine amide, undecapeptide is selected from the group consisting of L- arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-glycyl- L-leucyl-L-methionine amide, [D-Phe5, D-Trp7, D-Trp9, Leun]-SP, [Glp5, D-Trp7, D- Trp9, Thrn]-SP5.n, and [D-Arg1, D-Trp7, D-Trp9, Leun]-SP, hexapeptide amide is selected from the group consisting of Hpro-Phe-Phe-Dala-Leu-MetNH2, HPro-Phe- MePhe-Gly-Leu-MetNH2 and HPro-Phe-Phe-Gly-DLeu-MetNH2, di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amide is selected from the group consisting of H-trp-Phe-trp-Leu-Met-NH2, Hpro-trp-Phe-frp-Leu-Phe-NH2 and H-tpi-Phe-trp-Leu-Met-NH2, isoindolone is selected from the group consisting of 2-[l- imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4-perhydroisoindolone in its (3aR,7aR) or (3aR,7aRS) forms, 7,7-diphenyl-2-[2-(2-dimethylaminophenyl)acetyl]-4-perhydro- isoindolone in its (3aR,7aR) or (3aRS,7aRS) forms, 7,7-diphenyl-2-[(R)-2-(2-methoxy- phenyl)propionyl]-4-perhydroisoindolone in its (3aR,7aR) or (3aRS,7aRS) forms, diphenyl-7,7[dimethylamino-2 phenyl)-2 acetyl]-2 perhydroisoindolone-4, diphenyl- 7,7[methoxy-2 phenyl)-2 propionyl-(R)]-2 perhydroisoindolone-4 and [(5)-carboxy benzylimino-1 (methoxy-2 pheny l)-2 ethyl] -2 diphenyl-7,7 perhydro-isoindolone-4, quinuclidine is selected from the group consisting of cis-3-[(2-chlorophenyl)- methy lamino] -2-benzhydrylquinuclidine , cis-3-[(2-trifluoro-methy lphenyl)methyl- amino] -2-benzhydry lquinuclidine , cis-3 - [(2-methoxy-pheny l)methy lamino] -2-benz- hy dry lquinuclidine, 8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl))-9-azatricyclo- [4.3.1.04'9]decan-7-amine, 8-(diphenylmethyl)-N-(phenylmethyl)-9-azatricyclo- [4.3.1.04'9]decan-7-amine, 8-(diphenylmethyl)-N-((2-chlorophenyl)methyl))-9- azatricyclo[4.3.1.04,9]decan-7-amine, (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl- 2-diphenylmethyl-l-azabicyclo[2.2.2]octan-3-amine, (2S,3S)-N-(5-ethyl-2-methoxy- pheny l)methy 1-2-dipheny lmethy 1- 1 -azabicyclo [2.2.2] octan-3-amine , (2S , 3 S)-N-(5- isopr opy 1-2-methoxypheny l)methy 1-2-dipheny lmethy 1- 1 -azabicyclo [2,2.2] octan-3 -amine , (3R,4S,5S,6S)-N-carbamoylmethyl-5-(5-isopropyl-2-methoxybenzyl-amino)-6- diphenylmethyl-l-azabicyclo[2.2.2]octane-3-carboxamide, (3R,4S,5S,6S)-N-carboxy- memyl-5-(5-isopropyl-2-memoxybenzylamino)-6-diphenylmethyl-l-azabicyclo[2.2.2]- octane-3 -carboxamide and (3R,4S,5S,6S)-3-(2-carbamoylpyrrolidin-l-yl)carbonyl-5-(5- isopropy l-2-methoxybenzylamino)-6-dipheny lmethy 1- 1 -azabicyclo [2.2.2] octane , the peptide is selected from the group consisting of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe- Gly-Leuψ[CH2-NH]Leu-NH2, H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trpψ[CH2- NH]Leu-Nle-NH2, H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Tφψ[CH2-NH]Phe-D-Trp-Leu- Nle-NH2, Boc-Phe-(p-CH3)-OH, Boc-Phe-(p-F)-OH, Boc-Gin-D-Tφ(CHO)-Phe-NMe- Bzl, Boc-Thr-D-Tφ(CHO)-Phe-NMeBzl, Boc-Glu(NMe2)-D-Tφ(CHO)-Phe-NMeBzl, cyclo(Gln-Tφ-Phe-(R)Gly-[ANC-2]Leu-Met, cyclo(Gln-Npa-Phe-(R)Gly[ANC-2]Leu- Met and cyclo(Gln-Tφ-Phe-Gly-Leu-Met), spirolactam is selected from the group consisting of 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyl]-6-oxo-(5S)-l ,7-diaza- spiro[4.4]nonane-l-carboxylic acid, phenylmethyl ester, 7-[(lS)-(l-methoxycarbonyl)-3- methylbutyl]-6-oxo-(5S)-l ,7-diazaspiro[4.4]nonane-l-carboxylic acid phenylmethyl ester, 7-[(lS)-(l-methoxycarbonyl)-3-methylbutyl]-6-oxo-(5S)-l ,7-diazaspiro-
[4.4]nonane-l-carboxylic acid and (l,l-dimethyl)ethyl ester, 3-aminopiperidine and related nitrogen containing heterocycle is selected from the group consisting of cis-3-(2- methoxybenzylamino)-2-phenylpiperidine, cis-l-allyl-3-(2-methoxybenzylamino)-2- pheny lpiperidine , cis- 1 -ethy 1-3 -(2-methoxybenzylamino)-2-pheny lpiper idine , cis-3 -(2- chlorobenzylamino)-2-phenylpiperidine, cis-3-(2-trifluoromethylbenzylamino)-2- pheny lpiperidine, cis-3-(2-memoxybenzylamino)-2-(2-fluorophenyl)-piperidine, (2S,3S)- 3 -(4 , 5-difluoro-2-methoxybenzy l)amino-2-pheny 1-piper idine , (2S , 3 S)-3-(2- cyclopentyloxy-5-methoxybe_-zyl)amino-2-phenylpiperidine and (2S,3S)-3-(5-sec-butyl- 2-methoxybenzyl)amino-2-phenyl-piperidine, dialkylenepiperidino is selected from the group consisting of N-[4-(l-benzyl-4-piperidinyl)-2-(3,4-dichlorophenyl)-butyl]-4- fiuoronaphtalene carboxamide hydrochloride, N-[4-[l-(fluorobenzyl)-4-piperidinyl-2- (3 ,4-dichlorophenyl)-butyl]-2,4-dichlorobenzamide hydrochloride, N-methyl-N-[4-(l- benzyl-4-piperidinyl)-2(3,4-dichlorophenyl)-butyl]3-isopropoxyphenylacetamide hydrochloride, chlorohydrate of N-[{4-[l-benzyl-piperidin-4-yl]-2-(3,4-dichloro- phenyl)} -butyl] -4-fluoronaphtalenecarboxamide, chlorohydrate of N-[{2-(3,4-dichloro- phenyl)-4-[l-(4-fluorobenzyl)-piperidin-4-yl]}-butyl]-2,4-dichlorobenzamide and chlorohydrate of N-methyl-N-{{4-[l-benzyl-piperidine-4-yl]-2-(3,4-dichlorophenyl)}- butyl] -3 -isopropoxypheny lacetamide, the 1-acy lpiperidine is selected from the group consisting of (2R,4S) and (2R,4R)-2-benzyl-l-(3,5-dimethylbenzoyl)-N-(2-phenethyl)-4- piperidinamine hydrochloride, (2R*,4S*)-2-benzyl-l-(2-naphthoyl)-N-(4-quinolyl- methyl)-4-piperidinamine, (2R*,4S*)-2-benzyl-2-(3-trifluoro-methy_benzoyl)-N-(4- quinolylmethyl)-4-piperidinamine, (2R*,4S*)-2-benzyl-l-(2-naphthoyl)-N-(4-chinolyl- methyl)-4-piperidinamin, (2R*,4S*)-2-benzyl-l-(3-trifluoromethylbenzoyl)-N-(4- chinolylmethyl)-4-piperidinamin and (2R*,4S*)-2-benzyl-l-(3,5-bis-(trifluoromethyl)- benzoyl)-N-(4-chinolylmethyl)-4-piperidinamin, polycyclic amine is selected from the group consisting of 4-[2-(4-benzylpiperidin-l-yl)ethyl]-4-(3-methylphenyl)-l-(3- chlorophenyl)acetylpiperidine hydrochloride, 3-[2-(4-Benzylpiperidin-l-yl)ethyl]-3-(3,4- dichlorophenyl)-l-phenylacety lpiperidine hydrochloride, 5-[2-(4-benzylpiperidin-l- yl)ethyl]-5-(3,4-dichlorophenyl)-l-benzylpiperidinone hydrochloride, chlorhydrate of 5- [2-(4-benzyl-l-piperidinyl)ethyl]-5-(3,4-dichlorophenyl)-l-benzyl-piperidinone, chlorohydrate of 3-[2-(4-benzyl-l-piperidinyl)ethyl]-3-(3,4-dichlorophenyl)-l-phenyl- acety lpiperidine, chlorohydrate of 3-[2-(4-benzyl-l-piperidinyl)ethyl]-3-(3,4- dichlorophenyl)-l-(3-isopropoxy-phenyl)acetylazepine, the N-alkylenepiperidino is selected from the group consisting of N-[2-(3,4-dichlorophenyl)-4-(4-(2-pyridylthio)-l- piperidinyl)butyl]-2,4-dichlorobenzamide, N-[4-(4-N'-acetylanilino-l-piperidinyl)-2- (3,4-dichlorophenyl)butyl]-N-methylbenzamide and N-[4-(l-methyl-2-imidazolyl)-4- thio- l-piperidinyl)-2-naphthylbutyl]-2,4-dimethoxybenzamide, 3-amino-2-aryl- quinuclidine is selected from the group consisting of trans-2-phenyl-N-(2-methoxy- pheny l)methy 1)- 1 -azabicyclo [2.2.2] octan-3-amine , cis-2-pheny l-N-(pheny lmethy 1)- 1 - azabicyclo-[2.2.2]octan-3-amine and 2-(l-naphthyl)-N-((2-methoxyphenyl)methyl)-l- azabicyclo[2.2.2]octan-3-amine, isoquinolinyl is selected from the group consisting of N-[(6-chloro-l,2-dihydro-2-methyl-l-oxo-4-phenylisoquinolin-3-yl)methyl]-N'-
(3 isopropoxypheny l)urea, N-[( 1 , 2-dihydro-2 , 6 , 7-trimethyl- 1 -oxo-4-pheny lisoquinolin-3- yl)methyl]-N'-(3-methylphenyl)urea and N-[(l ,2-dihydro-2-methyl-l-oxo-4-phenyl- isoquinolin-3yl)methyl]-N'-(3-methylphenyl)urea, prolyl endopeptidase inhibitor compound is selected from the group consisting of (S)-2-[[(S)-2-(acetoxyacetyl)-l- pyrrolidiny 1] carbonyl] -N-(pheny lmethy 1)- 1 -pyrrolidinecarboxamide , (S)-2- [[(S)-2- (hydroxy acetyl)- 1 -pyrrolidinyl] carbonyl] -N-pheny lmethy 1- 1 -pyrrolidinecarboxamide and (S)-2-[[(S)-2-[(benzoyloxyacetyl)-l-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-l- pyrrolidinecarboxamide, pseudopeptide is selected from the group consisting of {l-[4- (lH-tetrazol-5-yl)butyl]indol-3-yl}carbonyl-Hyρ-Nal-NMeBzl, {l-[4-(lH-tetrazol-5- yl)butyl]indol-3-yl}carbonyl-Hyp-Tna-NMeBzl and { l-[4-(lH-tetrazol-5-yl)butyl]indol- 3-yl}carbonyl-Hyp-Thn-NMeBzl, piperidine is selected from the group consisting of (2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3trifluoromethoxyphenyl)piperidine, (2S,3S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine, (2S,3S)- 3-(2-ethoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine, l-[2-(5-fluoro-lH- indol-3-yl)ethyl]-4-[((2-methyl)phenylsulfιnyl)methyl]-4-piperidinol, l-[2-(5-fluoro-lH- indol-3-yl)ethyl]-4-[((4-methyl)phenylsulfϊnyl)methyl]-4-piperidinol and l-[2-(5-Fluoro- lH-indol-3-yl)ethyl]-4-[(phenylsulfinyl)methyl]-4-piperidinol, chromone compound is selected from the group consisting of (2R,4S)-N-[l-(3,5-bistrifluoromethylbenzoyl)-2- (4-chlorobenzyl)piperidin-4-yl]-4-oxo-4H-l-benzopyrene-2-carboxamide, (2R,4S)-N-[1- (3,5-bistrifluormethylbenzoyl)-2-benzylpiperidin-4-yl]-4-oxo-4H-l-benzopyrene-2- carboxamide and (2R,4S)-N-[l-(3 ,5-bistrifluoromethylbenzoyl)-2-(4-chloro-benzyl)- piper idin-4-yl] -6-fluoro-4-oxo-4H-l-benzopyrene-2-carboxam.de, perhydroisoindole is selected from the group consisting of {{ [(pyrrolidinyl- 1)-3 propoxy-2]phenyl}acetyl}-2 diphenyl-4,4 fluoro-7 perhydroisoindole, diphenyl-4,4 fluoro-7 [(methoxy-2 phenyl)-2 propionyl-(S)]-2 perhydroisoindole, [(dimethylamino-3 propoxy)-2 phenyl] acety 1-2 diphenyl-4,4 fluoro-7 perhydroisoindole, 7,7-dimethyl-4-(2-methoxyphenyl)-2-[2-(S)-(2- methoxyphenyl)propionyl]-4,5-perhydroisoindolediol, 4-(2-methoxyphenyl)-2-[2-(S)-(2- methoxyphenyl)proponyl]-5-methyl-4-perhydro-isoindolol, 2-[2-(S)-(2-hydroxy- phenyl)propionyl]-4-(2-methoxyphenyl)-6-methyl-4-perhydroisoindolol, diphenyl-7,7 (methoxy-2 phenyl)-4[(methoxy-2 phenyl)-2 propionyl]-2 perhydroisoindolol-4, diphenyl-7,7 (methoxy-2 phenyl)-4 [(methoxy -2 phenyl)-2 propionyl]-2 perhydroiso- indolediol-4,5 and diphenyl-7,7 (methoxy-2 phenyl)-4 [(hydroxy-2 phenyl)-2 acetyl]-2 perhydroisoindolol-4, substituted pyrrolidin-3yl-alkyl-piperidine is selected from the group consisting of (-r-)-or(-)-l-(2-[3-(3,4-dichloro-phenyl)-l-[2-(2-methoxy-phenyl)- acetyl]-pyrrolidin-3-yl]-ethyl)-4-phenyl-piperidine-4-carboxylic acid amide, (+)-or(-)-l- [2-[3-(3,4-dichloro-phenyl)-l(2,6-dimethoxy-benzoyl)-pyrrolidin-3-yl]-ethyl]-4-phenyl- piperidine-4-carboxylic acid amide and (+)-or(-)-l-[2-[3-(3,4-dichloro-phenyl)-l(3,4,5- trimethoxy-benzoyl)-pyrrolidin-3-yl]-ethyl]-4-phenyl-piperidine-4-carboxy lie acid amide, fused ring analog of nitrogen containing heterocycle is selected from the group consisting of [lα,3α,4α,5α] -4-(2-methoxybenzy l)amino-3 -pheny 1-2-azabicy clo- [3.3.0] octane, 4-(2-methoxybenzyl)amino-3-phenyl-2-azabicyclo[4.4.0]decane and 4-(2- methoxybe_ιzyl)amino-4-benzhydryl-3-azabicyclo[4.1.0]heptane, N-alkyl quinuclidinium salt is selected from the group consisting of (2S,3S)-cis-l-methyl-2-(diphenylmethyl)-N- ((2-methoxyphenyl)methyl)-l -azabicyclo [2.2.2] octan-3-amine iodide, (2S,3S)-cis-l-(4- carbethoxybutyl)-2-(dipheny lmethy l)-N-((2-methoxyphenyl)-methyl- 1 - azabicyclo[2.2.2]octan-3-amine iodide and (2S,3S)-cis-l-(4-carboethoxy-phenylmethyl)- 2-(diphenylmemyl)-N-((2-memoxyphenyl)methyl)-l-azabicyclo[2.2.2]-octan-3-amine iodide, l-azabicyclo[3.2.2] nonan-3-amine is selected from the group consisting of 2- (diphenylmethyl)-N-((2-methoxyphenyl)methyl)-azabicyclo[3.2.2]-nonan-3-amine, 2-
(diphenylmethyl)-N-((2-chlorophenyl)methyl)-l-azabicyclo[3.2.2]-nonan-3-amine and 2- (dipheny lmethy l)-N-((2 , 4-dimethoxypheny l)methy 1) - 1 -azabicyclo- [3.2.2] nonan-3 -amine , N,N-diacyl-piperazine is selected from the group consisting of l,4-bis(N,N-diphenyl- carbamoyl)piperazine-2-carboxylic acid, 1 ,4-bis(N,N-diphenyl-carbamoyl)-2-methyl- piperazine and l-(N,N-di-n-pentylcarbamoyl)-4-(N,N-diphenyl-carbamoyl)piperazine-2- carboxylic acid, substituted 3-aminoquinuclidine is selected from the group consisting of (3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoyxbenzyl-amino)-6-diphenylmethyl-l- azabicy clo [2.2.2] octane-3 -carboxamide, (3R,4S,5S,6S)-5-(5-isopropyl-2- methoxybenzy lamino)-6-dipheny lmethyl- 1 -azabicyclo [2.2.2] octane-3-carboxy lie acid and (3R,4S,5S,6S)-5-_;2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-l- azabicyclo[2.2.2]octane-3-carboxylic acid, azanorbornane compound is selected from the group consisting of (lSR,2SR,3SR,4RS)-l-aza-2-diphenylmethyl-3-[(2- methoxyphenyl)methylamino]bicyclo[2.2.1]heptane, (lSR,2SR,3SR,4RS)-l-aza-2- diphenylmethyl-3-[(2-methoxy-5-(l,l-dimethylethyl)phenyl)methylamino]-bicyclo- [2.2. l]heptane and (lSR,2SR,3SR,4RS)-l-aza-2-diphenylmethyl-3-[(2-methoxy-5- trifluoromethoxyphenyl)methylamino]bicyclo[2.2.1]heptane, fluoroalkoxybenzylamino derivative of nitrogen containing heterocycle is selected from the group consisting of (2S , 3 S)-2-pheny 1-3- [2-(2 , 2 , 2-tr ifluoroethoxy)-benzy 1] aminopiper idine , 2-(dipheny 1- methyl)-N-((2-difluoromethoxy)pheny l)methyl- 1 -azabicyclo [2.2.2] octan-3-amine and (2S,3S)-N-(2-methoxy-5-trifluoro-methoxyphenyl)methyl-2-diphenylmethyl-l-aza- bicyclo[2.2.2]octane-3-amine, fused tricyclic is selected from the group consisting of 1- (5H-dibenzo[a.d]cyclohepten-5-yl)-2-)3 ,5-dimethylbenzyloxy)ethylamine, N-acetamido- l-(5H-dibenzo[a,d]cyclohepten-5-yl)-2-(3,5-dimethylbenzyloxy)ethylamine and 1- (10,ll-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)-2-(3,5-dimethylbenzyl- oxy)ethylamine, aromatic compound is selected from the group consisting of 2- ammonium- 1 -((3 , 5-dimethylphenyl)-methyloxy)-3 ,3-diphenylpropane , 2-dimethyl- ammonium-l-((3,5-dimethylphenyl)-methyloxy)-3,3-diphenylpropane, 2-t-butoxy- carbonylamino-3,3-diphenylpropanoyl-(2-methoxyphenyl)methylamide, L-l-((3,5- bis(trifluoromethyl)phenyl)methyloxy)-2-(t-butoxycarbonylamino)-2-phenylethane, 1- ((3,5-dimethylphenyl)methyloxy)-2(S)-2-(((carbomethoxy)methyl)amino)-2-phenyl- ethane, (2S)-2-(((carboxamido)methyl)-ammonium-l-((3,5-dimethylphenyl)methyloxy)- 2-phenylethane, 3,5-dimethylbenzyl 2-(l,l-dimethylethoxycarbonylamino)-3-(3- indolyl)propionate, 2-methoxybenzyl 2-(l , l-dimethylethoxycarbonylamino)-3-(3- indolyl)propionate, 3,5-dimethylbenzyl 2-acetamido-3-(3-indolyl)propionate, 3,5- dimethylbenzyl 2-cyclohexanecarboxamido-3-(3-indolyl)propionate, 2-ammonium-3 ,3- diphenylpropanoyl-(2-methoxyphenyl) methylamide, (3 ,5-dimethylphenyl)methyl-2- ammonium-3 , 3-diphenylpropanoate and 2-methylammonium- 1 -((3 ,5-dimethylphenyl)- methyloxy)-3,3-diphenylpropane, fused tricyclic nitrogen containing heterocycle is selected from the group consisting of ( + )-cis-9-dipheny lmethy l-N-((2-methoxyphenyl)- methyl)-10-azatricyclo[4.4.1.O^jundecan-╬┤-amine ( +)-cis-9-dipheny lmethy l-N-(2- methoxy-5-chlorophenyl)-10-azatricyclo[4.4.1.O^lundecan-╬┤-amine and (+)-cis-9- diphenylmethyl-N-(2-trifluoromethoxyphenyl)-10-azatricyclo[4.4.1.05,7]undecan-8- amine, acyclic ethylenediamine is selected from the group consisting of 1-amino-l- phenyl-2-[(2-methoxy)phenylmethylamino]propane, (lR',2S')-l-cyclohexylamino-l- phenyl-2-[(2-methoxy)-phenylmethylamino]propane and 1 -N-cyclohexy 1- 1 -pheny 1-2-N ' - [(2-methoxy-5-trifluoromethoxyphenyl)methyl]- 1 ,2-ethanediamine, substituted benzylamino nitrogen containing non-aromatic heterocycle is selected from the group consisting of (2S,3S)-N-(2-methoxy-5-methylsulfonylphenyl)-methyl-2-diphenylmethyl- 1 -azabicyclo- [2.2.2] octan-3-amine , (2S , 3 S)-N-(2-methoxy-5-methy lthiopheny l)methy 1- 2-dipheny lmethy 1- 1 -azabicyclo [2.2.2] octan-3-amine and (2S , 3 S)-N-(2-methoxy-5- dimethylaminophenyl)methyl-2-diphenylmethyl-l-azabicyclo[2.2.2]octan-3-amine, substituted benzylaminoquinuclidine is selected from the group consisting of (2S,3S)-N- (5-isopropenyl-2-methoxyphenyl)methyl-2-diphenylmethyl-l-azabicyclo[2.2.2]octan-3- amine, (2S,3S)-N-(2-methoxy-5-vinylphenyl)methyl-2-diphenylmethyl-l-azabicyclo- [2.2.2]octan-3-amine and (2S,3S)-N-(2-methoxy-4,5-dimethylphenyl)methyl-2- dipheny lmethy 1- 1 -azabicyclo [2.2.2] octan-3 -amine , N-benzoy 1-4-oxy /thio-2-substituted piperidine is selected from the group consisting of (2R*,4S*)-2-benzyl-l-(3,5- bistrifluoromethylbenzoyl-4-(4-quinolylmethoxy)-piperidine, (2R*,4S*)-quinoline-3- carboxylic acid[2-benzyl-l-(3,5-bistrifluoromethylbenzoyl)-piperidin-4-yl]ester and
(2R* ,4S *)-2-benzy 1- 1 -(3 , 5 -bistrifluoromethy lbenzoy l-4-(3 -quinoly lmethoxy )-piper idine , aromatic amine is selected from the group consisting of N[(benzyl-4-piperidinyl-l)- 4(dichloro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide, N[(benzyl-4 piperidinyl-1)- 4(difluoro-3,4 phenyl)-2 butyl]-dichloro-2,4 benzamide and N[(benzyl-4 piperidinyl-1)- 4(dichloro-3,4 phenyl)-2 butyl] fluoro-4 naphthalene-1 carboxamide, azabicyclic is selected from the group consisting of trans-3-[3,5-bis(trifluoromethyl)benzyloxy]-2- (dipheny lmethy 1)-1 -azabicy clo [2.2.2] octane, trans-3-(3 ,5-dimethoxybenzyloxy)-2- (diphenylmethyl)-l-azabicyclo[2.2.2]octane, trans-2-(diphenylmethyl)-3-(3-phenoxy- benzyloxy)-l-azabicyclo[2.2.2]octane, 3-[(3 ,5-dimethylphenyl)methyloxy]-2-(l ,2- diphenylethy 1)- 1 -azabicyclo [2.2.2] octane and 3 - [(3 , 5-bistr ifluoromethy lpheny 1)- methy loxy] -2-( 1 , 2-dipheny lethy 1)- 1 -azabicyclo [2.2.2] octane , 3 - [(3 , 5 -bistri- fluoromethy lpheny l)methy loxy] -2- [ 1 -( 1 -(4-methoxypheny l)-2-pheny l)ethy 1] - 1 -azabicy clo [2.2.2] octane, thiopyranipyrrole is selected from the group consisting of {[(dimethylamino-3 propoxy-2) phenyl] acetyl)-6 dipheny 1-4, 4-oxyde-l perhydro- thiopyrano[2,3-c]pyrrole, { [(pyrrolidinyl- 1) -3 propoxy-2] phenyl} acetyl}-6 diphenyl- 4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole and [{methoxy-2 phenyl)-2 propionyl- (S)]-6 diphenyl-4,4 oxyde-1 perhydrothiopyrano[2,3-c]pyrrole and the azabicyclic is selected from the group consisting of cis-2-(diphenylmethyl-3-(3,5-dimethyl- benzyloxy)-l-methylpyrrolidine, cis-3-((3,5-dimethylphenyl)methyloxy)-2-phenyl- piperidine and cis-3-((3,5-dimethylphenyl)methyloxy-l-methyl-2-phenylpiperidine.
14. The method of Claim 11 containing a therapeutically effective amount of at least one other pharmacologically active substance (c).
15. The method of Claim 14 wherein the pharmacologically active substance (c) is selected from the group consisting of non-narcotic analgesics and narcotic analgesics.
16. The method of Claim 15 wherein the non-narcotic analgesic is selected from the group consisting of tramadol, acetaminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac.
17. . The method of Claim 15 wherein the narcotic analgesic is selected from the group consisting of codeine, dihydrocodeine, hydrocodone, levoφhanol, moφhine and oxycodone.
18. The method of Claim 11 wherein the nontoxic N-methyl-D- aspartate receptor antagomst is at least one member selected from the group consisting of dextromethoφhan, dextroφhan, amantadine, memantine and pharmaceutically acceptable salts thereof.
19. The method of Claim 12 wherein the nontoxic N-methyl-D- aspartate receptor antagonist is at least one member selected from the group consisting of dextromethoφhan, dextroφhan, amantadine, memantine and pharmaceutically acceptable salts thereof.
20. The method of Claim 11 wherein (a) and (b) are coadministered.
21. The method of Claim 18 wherein (a) and (b) are coadministered as a sustained release dosage form.
22. The method of Claim 11 wherein the pain is muscular pain, musculoskeletal pain, chronic pain, neuropathic pain or migraine.
PCT/US1998/010707 1997-08-11 1998-05-26 Substance p inhibitors in combination with nmda-blockers for treating pain WO1999007413A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76960/98A AU7696098A (en) 1997-08-11 1998-05-26 Substance p inhibitors in combination with nmda-blockers for treating pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5523397P 1997-08-11 1997-08-11
US60/055,233 1997-08-11

Publications (1)

Publication Number Publication Date
WO1999007413A1 true WO1999007413A1 (en) 1999-02-18

Family

ID=21996555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/010707 WO1999007413A1 (en) 1997-08-11 1998-05-26 Substance p inhibitors in combination with nmda-blockers for treating pain

Country Status (2)

Country Link
AU (1) AU7696098A (en)
WO (1) WO1999007413A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1014886A1 (en) * 1997-09-17 2000-07-05 Euro-Celtique S.A. Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US7087640B2 (en) * 2002-03-19 2006-08-08 Technology Commercialization Corp Substance with sedative effect
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US7687553B2 (en) 2004-08-27 2010-03-30 Schwarz Pharma Ag Method for treating bone cancer pain or chemotherapy induced pain
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7795275B2 (en) 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
US7794987B2 (en) 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US7820857B2 (en) 2004-06-09 2010-10-26 Ucb Pharma Gmbh Method for treating pain in trigeminal neuralgia
US7875652B2 (en) 2001-03-21 2011-01-25 Ucb Pharma Gmbh Method and composition for treating pain or tinnitus aureum
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US8008351B2 (en) 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8053476B2 (en) * 2001-03-20 2011-11-08 Ucb Pharma Gmbh Method for treating peripheral neuropathic pain
JP4854909B2 (en) * 2000-09-20 2012-01-18 メルク・シャープ・エンド・ドーム・コーポレイション Isoquinolinone potassium channel inhibitor
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US8309570B2 (en) 2001-06-07 2012-11-13 Analgesic Neuropharmaceuticals, Llc Treatment of central neuropathic pain
US8551950B2 (en) 2006-03-20 2013-10-08 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis of inflammatory pain
US8609630B2 (en) 2005-09-07 2013-12-17 Bebaas, Inc. Vitamin B12 compositions
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US9095557B2 (en) 2006-06-15 2015-08-04 Ucb Pharma Gmbh Anticonvulsant combination therapy
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292726A (en) * 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292726A (en) * 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MURRAY ET AL.: "Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model", PAIN, vol. 44, no. 2, February 1991 (1991-02-01), pages 179 - 185, XP002075555 *
OKANO ET AL.: "Effects of inthrathecally injected glutamate and substance P antagonists on repeated cold stress induced hyperalgesia in rats", BIOL. PHARMACEUT. BULL., vol. 18, no. 1, January 1995 (1995-01-01), pages 42 - 44, XP002075554 *
PRICE D D ET AL: "EFFECTS OF THE COMBINED ORAL ADMINISTRATION OF NSAIDS AND DEXTROMETHORPHAN ON BEHAVIORAL SYMPTOMS INDICATIVE OF ARTHRITIC PAIN IN RATS", PAIN, vol. 68, no. 1, November 1996 (1996-11-01), pages 119 - 127, XP002061724 *
REN ET AL.: "An isobolographic analysis of N-methyl-D-aspartate and NK1 Tachykinin receptor antagonists on inflammatory hyperalgesia in the rat", BRIT. J. PHARMACOL., vol. 117, no. 1, January 1996 (1996-01-01), pages 196 - 202, XP002075553 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685994B2 (en) 1997-09-17 2014-04-01 Purdue Pharma, L.P. Analgesic combination of oxycodone and celecoxib
US8188107B2 (en) 1997-09-17 2012-05-29 Purdue Pharma L.P. Analgesic combination of oxycodone and N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide
US6552031B1 (en) 1997-09-17 2003-04-22 Euro-Celtique S.A. Synergistic analgesic combination of oxycodone and rofecoxib
EP1518555A1 (en) * 1997-09-17 2005-03-30 Euro-Celtique S.A. Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US8143267B2 (en) 1997-09-17 2012-03-27 Purdue Pharma L.P. Analgesic combination of oxycodone and nimesulide
EP1014886A1 (en) * 1997-09-17 2000-07-05 Euro-Celtique S.A. Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
EP1014886A4 (en) * 1997-09-17 2001-10-17 Euro Celtique Sa Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
CZ300531B6 (en) * 1997-09-17 2009-06-10 Euro-Celtique S.A. Pharmaceutical medicament form for individual administration and its use
US8168629B2 (en) 1997-09-17 2012-05-01 Purdue Pharma L.P. Analgesic combination of tramadol and meloxicam
US8193209B2 (en) 1997-09-17 2012-06-05 Purdue Pharma L.P. Analgesic combination of oxycodone and meloxicam
JP4854909B2 (en) * 2000-09-20 2012-01-18 メルク・シャープ・エンド・ドーム・コーポレイション Isoquinolinone potassium channel inhibitor
US8053476B2 (en) * 2001-03-20 2011-11-08 Ucb Pharma Gmbh Method for treating peripheral neuropathic pain
US7875652B2 (en) 2001-03-21 2011-01-25 Ucb Pharma Gmbh Method and composition for treating pain or tinnitus aureum
US8309570B2 (en) 2001-06-07 2012-11-13 Analgesic Neuropharmaceuticals, Llc Treatment of central neuropathic pain
US7087640B2 (en) * 2002-03-19 2006-08-08 Technology Commercialization Corp Substance with sedative effect
US8809010B2 (en) 2003-05-05 2014-08-19 Probiodrug Ag Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7794987B2 (en) 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US8008351B2 (en) 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
US7820857B2 (en) 2004-06-09 2010-10-26 Ucb Pharma Gmbh Method for treating pain in trigeminal neuralgia
US8338641B2 (en) 2004-06-09 2012-12-25 Ucb Pharma Gmbh Method for treating atypical facial pain
US8536137B2 (en) 2004-08-27 2013-09-17 Ucb Pharma Gmbh Methods for treating nucleoside-induced pain
US7687553B2 (en) 2004-08-27 2010-03-30 Schwarz Pharma Ag Method for treating bone cancer pain or chemotherapy induced pain
US8404686B2 (en) 2004-12-24 2013-03-26 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US7795275B2 (en) 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
US8722675B2 (en) 2004-12-24 2014-05-13 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US8492382B2 (en) 2004-12-24 2013-07-23 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US8609630B2 (en) 2005-09-07 2013-12-17 Bebaas, Inc. Vitamin B12 compositions
US9227968B2 (en) 2006-03-20 2016-01-05 Novartis Ag Method of treatment or prophylaxis of inflammatory pain
US8551950B2 (en) 2006-03-20 2013-10-08 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis of inflammatory pain
US9095557B2 (en) 2006-06-15 2015-08-04 Ucb Pharma Gmbh Anticonvulsant combination therapy
US9446011B2 (en) 2006-06-15 2016-09-20 Ucb Pharma Gmbh Anticonvulsant combination therapy
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
AU7696098A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
WO1999007413A1 (en) Substance p inhibitors in combination with nmda-blockers for treating pain
US6007841A (en) Analgesic composition and method for treating pain
US6054451A (en) Analgesic composition and method for alleviating pain
US6187338B1 (en) Anticonvulsant containing composition for treating neuropathic pain
US6043244A (en) Method and composition for treating migraine
US5919826A (en) Method of alleviating pain
AU2003210486B2 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
ES2435722T3 (en) Noribogaine in the treatment of pain and drug addiction
US20020035105A1 (en) Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain
EP0615749A2 (en) Use of NMDA antagonists for the treatment of pain
AU2003210486A1 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
US5834479A (en) Method and composition for alleviating pain
JPH10505087A (en) Pain relieving composition containing non-narcotic analgesic and painless enhancer
Hersh et al. Narcotic receptor blockade and its effect on the analgesic response to placebo and ibuprofen after oral surgery
US20090023780A1 (en) Therapeutic use of a derivative of thienylcyclohexylamine
US6828328B1 (en) Analgesic combination of muscarinic agonists
US5908847A (en) Combination of a β-receptor blocker and an opioid
US20080287480A1 (en) Therapeutic Combination Comprising a Nmda Receptors Blocker and a Narcotic Analgesic Substance
US20050187239A1 (en) Synergistic l-methadone compositions and methods of use thereof
Freye et al. Postoperativer Einsatz von Opioiden

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase